Author: "Clinique des Maladies Mentales et de l'Encéphale" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Clinique des Maladies Mentales et de l'Encéphale"' showing total 269 results

Start Over Author "Clinique des Maladies Mentales et de l'Encéphale"

269 results on '"Clinique des Maladies Mentales et de l'Encéphale"'

1. Les troubles du comportement alimentaire

Author: La Clinique des Maladies Mentales et de l'Encéphale
Published: 2022

2. Définition médico-légale de l'aliéné : leçon d'ouverture du cours de psychiatrie médico-légale / par M. le Dr Ernest Dupré,... ; Clinique des maladies mentales, Institut de médecine légale de de psychiatrie

Author: Clinique des maladies mentales et de l'encéphale (Paris). Éditeur scientifique, Institut de médecine légale et de psychiatrie (Paris). Éditeur scientifique, Dupré, Ernest (1862-1921). Auteur du texte, Clinique des maladies mentales et de l'encéphale (Paris). Éditeur scientifique, Institut de médecine légale et de psychiatrie (Paris). Éditeur scientifique, and Dupré, Ernest (1862-1921). Auteur du texte
Published: 1904

3. Attention-Déficit Hyperactivity Disorder Symptoms and Psychological Comorbidity in Eating Disorder Patients

Author: Sala , Loretta, Martinotti , Giovanni, Carenti , ML, Romo , Lucia, Oumaya , M, Pham-Scottez , Alexandra, Rouillon , Frederic, Gorwood , Philip, Janiri , Luigi, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Hôpital Sainte-Anne, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne
Subjects: [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SHS.PSY ] Humanities and Social Sciences/Psychology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.PSYC]Cognitive science/Psychology, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, [No keyword], ComputingMilieux_MISCELLANEOUS
Abstract: International audience; [No abstract]
Published: 2017

4. Mimetic desire in autism spectrum disorder

Author: Maël Lebreton, Fabien Vinckier, Mathias Pessiglione, Laurent Mottron, Baudouin Forgeot d’Arc, Isabelle Soulières, Université de Montréal (UdeM), Centre intégré universitaire du Nord de l'île de Montréal, ASD Specialized clinic, Montréal, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Université du Québec à Montréal = University of Québec in Montréal (UQAM), HAL UPMC, Gestionnaire, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Université de Montréal [Montréal], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -CHU Pitié-Salpêtrière [APHP], Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, and Université du Québec à Montréal ( UQAM )
Subjects: Male, 0301 basic medicine, Anhedonia, Autism Spectrum Disorder, Autism, Developmental psychology, Social influence, 0302 clinical medicine, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Social perception, Neuropsychology, Mirror neuron system, Social cognition, Psychiatry and Mental health, Social Perception, Autism spectrum disorder, Mimetic desire, Female, medicine.symptom, Psychology, Restricted interests, Clinical psychology, Adult, Brain valuation system, Adolescent, Short Report, behavioral disciplines and activities, Judgment, 03 medical and health sciences, Developmental Neuroscience, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, mental disorders, medicine, Humans, Molecular Biology, Motivation, Psychological Tests, medicine.disease, Imitative Behavior, Social relation, Social motivation, 030104 developmental biology, Case-Control Studies, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Developmental Biology
Abstract: International audience; Mimetic desire (MD), the spontaneous propensity to pursue goals that others pursue, is a case of social influence that is believed to shape preferences. Autism spectrum disorder (ASD) is defined by both atypical interests and altered social interaction. We investigated whether MD is lower in adults with ASD compared to typically developed adults and whether MD correlates with social anhedonia and social judgment, two aspects of atypical social functioning in autism. Contrary to our hypotheses, MD was similarly present in both ASD and control groups. Anhedonia and social judgment differed between the ASD and control groups but did not correlate with MD. These results extend previous findings by suggesting that basic mechanisms of social influence are preserved in autism. The finding of intact MD in ASD stands against the intuitive idea that atypical interests stem from reduced social influence and indirectly favors the possibility that special interests might be selected for their intrinsic properties.
Published: 2016
Full Text: View/download PDF

5. Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis

Author: Georgin-Lavialle, Sophie, Moura, Daniela Silva, Salvador, Alexandre, Chauvet-Gélinier, Jean-Christophe, Launay, Jean-Marie, Damaj, Ghandi, Côté, F., Soucié, Erinn, Chandesris, Marie-Olivia, Barète, Stéphane, Grandpeix-Guyodo, Catherine, Bachmeyer, Claude, Alyanakian, Marie-Alexandra, Aouba, Achille, Lortholary, Olivier, Dubreuil, Patrice, Teyssier, Jean-Raymond, Trojak, Benoit, Haffen, Emmanuel, Vandel, Pierre, Bonin, Bernard, Hermine, Olivier, Gaillard, Raphaël, Beyne-Rauzy, Odile, De Gennes, Christian, Durieu, Isabelle, Fain, O, Grosbois, Bernard, Guichard, Isabelle, Hamidou, Mohamed, Launay, David, Lavigne, Christian, Livideanu, Christina, Nicolini, Franck, Retornaz, R, Arock, Michel, Arlet, Jean-Benoit, Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de référence des mastocytoses, CHU Necker - Enfants Malades [AP-HP], Laboratoire de Psychopathologie et Processus de Santé (LPPS - EA 4057), Université Paris Descartes - Paris 5 (UPD5), Laboratoire de physiopathologie des maladies psychiatriques, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Service de psychiatrie générale et addictologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire de psychopathologie et psychologie médicale (LPPM), Université de Bourgogne (UB), Service de biochimie INSERM UMR-S942, Hôpital Lariboisière-APHP, Service hématologie Amiens, CHU Amiens-Picardie, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Centre d'infectiologie Necker-Pasteur [CHU Necker], Laboratoire de Génétique Moléculaire, Département de psychiatrie [CHU de Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC), Centre d'Investigation Clinique de Besançon (CICB), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement Français du Sang Bourgogne Franche-Comté-Université de Franche-Comté (UFC), Histopathologie humaine et Modèles animaux, Institut Pasteur [Paris], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de référence des mastocytoses (CEREMAST), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Hématologie [CHU Amiens], Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Laboratoire de génétique moléculaire (hôpital général, CHU Dijon), Hôpital général (CHU Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Département de psychiatrie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Institut Pasteur [Paris] (IP), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Laboratoire de Psychopathologie et Processus de Santé ( LPPS - EA 4057 ), Université Paris Descartes - Paris 5 ( UPD5 ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire de psychopathologie et psychologie médicale ( LPPM ), Université de Bourgogne ( UB ), Centre de Recherche en Cancérologie de Marseille ( CRCM ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université ( AMU ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) ( NEURO ), Université Bourgogne Franche-Comté [COMUE] ( UBFC ) -Université de Franche-Comté ( UFC ), Centre d'Investigation Clinique de Besançon ( CICB ), Etablissement Français du Sang Bourgogne Franche-Comté-Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Franche-Comté ( UFC ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Male, 0301 basic medicine, [SHS.PSY]Humanities and Social Sciences/Psychology, Kynurenic Acid, chemistry.chemical_compound, 0302 clinical medicine, Kynurenic acid, Mast Cells, Indoleamine 2,3-dioxygenase, Acute stress, Quinolinic acid, Kynurenine, Depression (differential diagnoses), Depression, Tryptophan, Middle Aged, Mast cell, Rat-brain, 3. Good health, Psychiatry and Mental health, medicine.anatomical_structure, [ SCCO.NEUR ] Cognitive science/Neuroscience, Female, medicine.symptom, Mastocytosis, Serotonin, medicine.medical_specialty, Inflammation, Aryl-hydrocarbon receptor, Central-nervous-system, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 03 medical and health sciences, Cellular and Molecular Neuroscience, Internal medicine, medicine, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Molecular Biology, Psychiatric Status Rating Scales, Depressive Disorder, Major, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Beck Depression Inventory, Interferon-alpha, Mammalian brain, 030104 developmental biology, Endocrinology, Immune-system, chemistry, Immunology, Indoleamine 2?3-dioxygenase, business, Stress, Psychological, 030217 neurology & neurosurgery
Abstract: International audience; Converging sources of evidence point to a role for inflammation in the development of depression, fatigue and cognitive dysfunction. More precisely, the tryptophan (TRP) catabolism is thought to play a major role in inflammation-induced depression. Mastocytosis is a rare disease in which chronic symptoms, including depression, are related to mast cell accumulation and activation. Our objectives were to study the correlations between neuropsychiatric features and the TRP catabolism pathway in mastocytosis in order to demonstrate mast cells' potential involvement in inflammation-induced depression. Fifty-four patients with mastocytosis and a mean age of 50.1 years were enrolled in the study and compared healthy age-matched controls. Depression and stress were evaluated with the Beck Depression Inventory revised and the Perceived Stress Scale. All patients had measurements of TRP, serotonin (5-HT), kynurenine (KYN), indoleamine 2,3-dioxygenase 1 (IDO1) activity (ratio KYN/TRP), kynurenic acid (KA) and quinolinic acid (QA). Patients displayed significantly lower levels of TRP and 5-HT without hypoalbuminemia or malabsorption, higher IDO1 activity, and higher levels of KA and QA, with an imbalance towards the latter. High perceived stress and high depression scores were associated with low TRP and high IDO1 activity. In conclusion, TRP metabolism is altered in mastocytosis and correlates with perceived stress and depression, demonstrating mast cells' involvement in inflammation pathways linked to depression.
Published: 2016
Full Text: View/download PDF

6. Les interventions sur Internet, destinées aux étudiants souffrant de binge drinking. Revue de la littérature

Author: Lucia Romo, Alexandra Dereux, Marie Vrillon, Philip Gorwood, Laurence Kern, HAL Nanterre, Administrateur, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Centre de Recherche sur le Sport et le Mouvement (CeRSM), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Centre de Recherche sur le Sport et le Mouvement ( CeRSM ), Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne
Subjects: [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 05 social sciences, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, 050109 social psychology, General Medicine, 030227 psychiatry, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SHS.PSY] Humanities and Social Sciences/Psychology, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 03 medical and health sciences, 0302 clinical medicine, [SCCO.PSYC]Cognitive science/Psychology, [SCCO.PSYC] Cognitive science/Psychology, 0501 psychology and cognitive sciences, [No keyword], ComputingMilieux_MISCELLANEOUS
Abstract: Le binge drinking (consommation ponctuelle importante d’alcool) est un mode de consommation d’alcool frequemment utilise par les etudiants. Les consequences d’une consommation excessive sont nombreuses et il est important d’aider les jeunes qui en souffrent. Les interventions sur Internet (IBI) semblent etre une methode efficace pour les aider a prendre conscience de la dangerosite du binge drinking. Les bases de donnees Medline et PsycINFO ont ete consultees pour effectuer cette revue de la litterature. Le composant principal des IBI est le compte rendu personnalise, accompagne d’informations, de comparaisons normatives, de conseils, etc. Les IBI analysees ont, dans l’ensemble, ete efficaces sur la population etudiante. Malgre une efficacite averee et de nombreux avantages, ce type d’intervention est peu repandu et doit encore se developper, afin de mieux s’adapter aux jeunes.
Published: 2015

7. Clinical features and outcomes of COVID-19 patients hospitalized for psychiatric disorders: a French multi-centered prospective observational study

Author: Claire Jansen, Pierre Thomas, Djamila Bennabi, Dominique Drapier, Thomas Schwitzer, Delphine Capdevielle, Noe Teboul, Pascal Delamillieure, Emmanuelle Corruble, Christophe Schmitt, Daniela Dobre, Olivier C. Martin, Pierre Abdel Ahad, Antoine Pelissolo, Clément Vansteene, Benjamin Rolland, Marion Leboyer, Raymund Schwan, Fabienne Ligier, Wanda Yekhlef, Antoine Yrondi, Raphaël Gaillard, William Lecoeur, Radoine Haoui, Mathilde Roser, Vincent Laprevote, Catherine Massoubre, Sonia Dollfus, Fabien Joubert, Philip Gorwood, Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, Centre Psychothérapique de Nancy [Laxou] (CPN), Faculté de Médecine [Nancy], Université de Lorraine (UL), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), GHU Paris Psychiatrie et Neurosciences, Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département de psychiatrie adulte, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital La Colombière, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Imagerie et Stratégies Thérapeutiques de la Schizophrénie (ISTS), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes], Université de Rennes (UR)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes = Institute of Clinical Neurosciences of Rennes (INCR), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier le Vinatier [Bron], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), Service Psychiatrie et psychologie médicale [CHU Toulouse], Pôle Psychiatrie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Gérard Marchant, Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre de Psychiatrie et Neurosciences (U894), Centre Psychothérapique de Nancy (CPN), Université de Rennes (UR)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, HAL UR1, Admin, Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Universitaire d’Addictologie de Lyon [CH Le Vinatier, Bron] (Pôle MOPHA - SUAL), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR), Etablissement Public de Santé Alsace Nord, Partenaires INRAE, Hôpital Sainte-Anne-Université de Paris (UP), Etablissement public de santé de Ville-Evrard (EPS), Service Psychiatrie et psychologie médicale [CHU Purpan], CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Population, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Confusional state, Logistic regression, Lower risk, 03 medical and health sciences, 0302 clinical medicine, Organic mental disorders, Intensive care, medicine, Psychiatry, Prospective cohort study, education, Applied Psychology, Univariate analysis, education.field_of_study, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, Medical record, COVID-19, Odds ratio, medicine.disease, Mental health, Confidence interval, 030227 psychiatry, 3. Good health, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Original Article, Observational study, business, 030217 neurology & neurosurgery
Abstract: Background: At the beginning of COVID-19 pandemic, specific COVID/PSY wards were created in France to provide care for inpatients with COVID-19 and psychiatric disorders. In this multi-center prospective study, we set out to assess the clinical features and risk factors of somatic aggravation in patients hospitalized in COVID/PSY wards. Methods: Data were collected between 28 February and 30 May, 2020. We collected demographic data, psychiatric diagnoses, medical data and COVID-19-related clinical data. Somatic aggravation was estimated by the number of patients transferred to intensive care or medicine units, the number of deaths and the number of patients presenting a confusional state. A multivariate logistic model was used to assess the risk factors of confusional state and transfer to intensive care or medicine units. The risk of death was analysed by the univariate predictors of this outcome. Outcomes: 350 patients were included in the study. The number of inclusions peaked one week after that of the general population and declined more slowly. Overall, 24 (7%) were transferred to medicine units, 7 (2%) died and 51 (15%) patients presented a confusional state. Severe respiratory symptoms predicted the transfer to a medicine unit (OR 17.1; CI 4.9-59.3). Older age, an organic mental disorder, a confusional state, and severe respiratory symptoms predicted mortality in univariate analysis. Age > 55 (OR 4.9; CI 2.1-11.4), an affective disorder (OR 4.1; CI 1.6-10.9), and severe respiratory symptoms (OR 4.6; CI 2.2-9.7) predicted a higher risk, while smoking (OR 0.3; CI 0.1-0.9) predicted a lower risk of a confusional state. Interpretation: COVID-19 patients with severe psychiatric disorders have multiple somatic comorbidities and a high risk of confusion. COVID/PSY wards may play a role in reducing the mortality of COVID-19 in patients with psychiatric disorders. Funding Statement: There was no funding source for this study. Declaration of Interests: There are no conflicts of interest to be declared. Ethics Approval Statement: This observational study was conducted according to the principles of the Declaration of Helsinki. In accordance with French bioethics laws, it was classified as a non- interventional study, since it concerned anonymized clinical data that are routinely compiled in medical records. Compliance with French regulations on personal data collection was supervised by the personal data referent of the Centre Psychotherapique de Nancy. Patients, and their legal guardian when appropriate, were informed in writing, in agreement with national regulations for observational studies.
Published: 2023
Full Text: View/download PDF

8. The structure of the Montgomery-Åsberg depression rating scale over the course of treatment for depression

Author: Quilty, Lena C., Robinson, Jennifer J., Rolland, Jean-Pierre, Fruyt, Filip De, Rouillon, Frédéric, Bagby, R. Michael, Centre de Recherche sur le Sport et le Mouvement ( CeRSM ), Université Paris Nanterre ( UPN ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Centre de Recherche sur le Sport et le Mouvement (CeRSM), Université Paris Nanterre (UPN), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), and Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne
Subjects: Adult, Male, confirmatory factor analysis, Paris, gender invariance, Adolescent, Psychometrics, Thiazepines, assessment, [ SCCO.PSYC ] Cognitive science/Psychology, Personality Assessment, Young Adult, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Sex Factors, Fluoxetine, Ambulatory Care, Humans, Longitudinal Studies, Models Psychological, Aged, Psychotherapy Psychodynamic, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Reproducibility of Results, Social Support, Emotion Cognition et Comportement, Middle Aged, Depressive Disorder Major, Combined Modality Therapy, Psychotherapy, Cognitive Therapy, [SCCO.PSYC]Cognitive science/Psychology, Female, major depression
Abstract: International audience; The Montgomery-Åsberg Depression Rating Scale (MADRS) is a widely used clinician-rated measure of depressive severity. Empirical support for the factor structure of the MADRS is mixed; further, the comparison of MADRS scores within and between patients requires the demonstration of consistent instrument properties. The objective of the current investigation was to evaluate MADRS factor structure as well as MADRS factorial invariance across time and gender. The MADRS was administered to 821 depressed outpatients participating in a large-scale effectiveness study of combined pharmacotherapy and psychotherapy for depression. Treatment outcome did not differ across treatment groups. Factor structure and invariance was evaluated via confirmatory factor analysis. A four-factor model consisting of Sadness, Negative Thoughts, Detachment and Neurovegetative symptoms demonstrated a good fit to the data. This four-factor structure was invariant across time and gender. A hierarchical model, in which these four factors served as indicators of a general depression factor, was also supported. A limitation of the current study is the lack of comprehensive characterization of patient clinical features; results need to be replicated in more severely depressed or treatment refractory patients. Overall, evidence supported the use of the MADRS total score as well as subscales focused on affective, cognitive, social and somatic aspects of depression in male and female outpatients.
Published: 2013
Full Text: View/download PDF

9. Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa

Author: Luis San, Ludger Hargarter, Philip Gorwood, Andreas Schreiner, Tom Burns, Georg Juckel, Alessandro Rossi, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Psychiatry, University of Oxford [Oxford]-Warneford Hospital, Psychiatrie, LWL-Universitaetsklinikum der Ruhr-Universitaet Bochum, Department of Experimental Medicine, Università degli Studi dell'Aquila (UNIVAQ), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Hospital Sant Joan de Déu [Barcelona], Department of Medical and Scientific Affairs, Janssen EMEA, Europe, Middle East and Africa functioning group, Centre de Psychiatrie et Neurosciences (U894), University of Oxford-Warneford Hospital, Università degli Studi dell'Aquila = University of L'Aquila (UNIVAQ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Università degli Studi dell'Aquila [L'Aquila] ( UNIVAQ.IT ), Centro de Investigación Biomédica en Red de Salud Mental ( CIBERSAM ), and BMC, Ed.
Subjects: medicine.medical_specialty, Psychiatrist, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, media_common.quotation_subject, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Psychological intervention, Assessment, behavioral disciplines and activities, 03 medical and health sciences, 0302 clinical medicine, Perception, Forensic psychiatry, mental disorders, Medicine, Functioning, Psychiatry, Survey, media_common, Middle East, business.industry, medicine.disease, 030227 psychiatry, 3. Good health, Management, Psychiatry and Mental health, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Primary Research, business, Psychosocial, 030217 neurology & neurosurgery, Geriatric psychiatry, Independent living, Clinical psychology
Abstract: Background: It has been estimated that as many as two thirds of patients with schizophrenia are unable to perform basic personal and social roles or activities. Occupational functioning and social functioning, as well as independent living, are considered as core domains of patient functioning. Improvement in patient functioning has also been recognized as an important treatment goal in guidelines and an important outcome by regulatory agencies. Nevertheless, information is lacking on how these aspects are being considered by psychiatrists across the world and how they are being assessed and managed.Methods: The 'Europe, the Middle East and Africa functioning survey' was designed to canvas opinions of psychiatrists across these regions to ascertain their perceptions of the clinical importance, assessment and management of functioning amongst their patients with schizophrenia. The survey comprised 17 questions and was conducted from March to April 2011 in 42 countries. Data collected included the demographics of respondents and their opinions regarding personal and social functioning in patients with schizophrenia.Results: Results were obtained from 4,163 clinicians. Psychiatrists estimated that more than two thirds (70%) of their patients with schizophrenia showed impaired or very poor levels of functioning. The majority of psychiatrists (92%) believed that personal and social functioning was an important treatment goal for patients with schizophrenia, and 91% believed it was an important goal for patients' families. The majority of psychiatrists (55%) assess the personal and social functioning of their patient at each visit; however, 81% reported that they determine the level of functioning through clinical interview and not by using a specific assessment scale. To manage personal and social functioning in their patients, 26% of psychiatrists prefer pharmacological interventions, whereas 46% prefer psychosocial interventions.Conclusion: Psychiatrists recognize that functioning is impaired/very poor in patients with schizophrenia, and there is still an important need to address functioning as a main treatment goal for patients with schizophrenia. © 2013 Gorwood et al.; licensee BioMed Central Ltd.
Published: 2013
Full Text: View/download PDF

10. Towards a universal neurobiological architecture for learning to read

Author: Marcin Szwed, Laurent D. Cohen, Fabien Vinckier, Stanislas Dehaene, Unité de neurosciences intégratives et computationnelles ( UNIC ), Centre National de la Recherche Scientifique ( CNRS ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -CHU Pitié-Salpêtrière [APHP], Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière ( CRICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Service de neurologie 2 [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Neuroimagerie cognitive ( UNICOG-U992 ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Collège de France ( CDF ), Collège de France ( CdF ), Unité de neurosciences intégratives et computationnelles (UNIC), Centre National de la Recherche Scientifique (CNRS), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Neuroimagerie cognitive - Psychologie cognitive expérimentale (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Saclay (COmUE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Chaire Psychologie cognitive expérimentale, Collège de France (CdF (institution)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Collège de France - Chaire Psychologie cognitive expérimentale, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Neuroimagerie cognitive (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Collège de France (CDF), and Collège de France (CdF)
Subjects: Cognitive science, Physiology, Computer science, media_common.quotation_subject, 05 social sciences, [ SCCO.PSYC ] Cognitive science/Psychology, Universal model, 050105 experimental psychology, 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, Neuropsychology and Physiological Psychology, Reading (process), [SCCO.PSYC]Cognitive science/Psychology, Learning to read, 0501 psychology and cognitive sciences, Architecture, Neural coding, 030217 neurology & neurosurgery, Cognitive psychology, media_common
Abstract: Letter-position tolerance varies across languages. This observation suggests that the neural code for letter strings may also be subtly different. Although language-specific models remain useful, we should endeavor to develop a universal model of reading acquisition which incorporates crucial neurobiological constraints. Such a model, through a progressive internalization of phonological and lexical regularities, could perhaps converge onto the language-specific properties outlined by Frost.
Published: 2012
Full Text: View/download PDF

11. A first national survey of knowledge, attitudes and behaviours towards schizophrenia, bipolar disorders and autism in France

Author: Frédéric Rouillon, Isabelle Durand-Zaleski, Marion Leboyer, Jan Scott, Département de santé publique et psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-URCEco, FondaMental Foundation, Fondation de Coopération Scientifique Hôpital, A. Chenevier, EA 44393, Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Academic Psychiatry, Newcastle University [Newcastle], Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, This research was supported by Institut National de la Santé et de la Recherche Médicale (INSERM) and Fondation FondaMental (Fondation de Coopération Scientifique pour le développement de la recherche et des soins en santé mentale)., Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-URCEco, Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, and BMC, Ed.
Subjects: Male, Health Knowledge, Attitudes, Practice, Bipolar Disorder, Social stigma, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Autism, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Social Stigma, Behaviours, Mind-blindness, 0302 clinical medicine, Surveys and Questionnaires, lcsh:Psychiatry, Discrimination, Young adult, Survey, 10. No inequality, education.field_of_study, Social distance, 05 social sciences, Middle Aged, Psychiatry and Mental health, Female, Mental health, France, Psychology, Research Article, 050104 developmental & child psychology, Clinical psychology, Adult, medicine.medical_specialty, Adolescent, lcsh:RC435-571, Population, Young Adult, 03 medical and health sciences, mental disorders, Bipolar disorders, medicine, Humans, 0501 psychology and cognitive sciences, Bipolar disorder, Autistic Disorder, Psychiatry, education, Aged, Internet, medicine.disease, Health Surveys, 030227 psychiatry, Stigma, Attitudes, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Schizophrenia, Feasibility Studies
Abstract: Background In order to support evidence-based policies for reduction of stigma, a better understanding of its components: ignorance (knowledge), prejudice (attitude) and discrimination (behaviour) is necessary. This study explores public perceptions and quantifies stigma for three chronic mental disorders: autism, schizophrenia and bipolar disorders in France. Methods Survey of 1000 adults selected from an established market research panel. The 21-item questionnaire explored knowledge, attitudes and behaviours toward each disorder. Results Although 95% respondents recognized the names of each disorder fewer than 70% could report specific characteristics and only 33% considered that publically available information was adequate; most respondents identified the media as their main resource. Labeling of conditions in a negative way was frequent (61%) when referring to mental disorders in general, but fell significantly (18%) when linked to an individual with a disorder. Individuals with schizophrenia are assumed to be dangerous; 65% respondents would engage in social distancing from such an individual, versus 29% for bipolar disorders and 7% for autism (p Conclusion This first population-based survey in France shows that attitudes towards bipolar disorders and autism are less prejudicial than towards schizophrenia. However, most public attitudes and behaviours towards different disorders appear to be based on assumptions rather than knowledge or evidence suggesting a generic information or anti-stigma programme is unlikely to be effective.
Published: 2012
Full Text: View/download PDF

12. Estrogen receptor 1 gene (ESR1) is associated to restrictive anorexia nervosa

Author: VERSINI, Audrey, RAMOZ, Nicolas, Le Strat, Yann, Friedel, Susann, Ehrlich, Stefan, Boni, Claudette, Hinney, Anke, Hebebrand, Johannes, Romo, Lucia, Guelfi, Julien-Daniel, Gorwood, Philip A.P.M., Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Department of Child and Adolescent Psychiatry, Universität Duisburg-Essen [Essen], Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charite-Universitatsmedizin Berlin [Berlin], Service de psychiatrie [Mourier], Assistance publique - Hôpitaux de Paris (AP-HP)-Hopital Louis Mourier - AP-HP [Colombes], Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Evaluation clinique des troubles psychopathologiques et des psychothérapies (EVACLIPSY), Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN)-Université Paris Nanterre (UPN), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Centre de Psychiatrie et Neurosciences (U894), and Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Subjects: body regions, population-based sample, [SHS.PSY]Humanities and Social Sciences/Psychology, Eating/Metabolic Disorders, estrogen receptors, Anorexia nervosa, restrictive type, Neurogenetics, Molecular & Cellular Neurobiology, transmission disequilibrium test, binge-eating/purging type, Biological Psychiatry
Abstract: International audience; Anorexia nervosa is a highly heritable young-onset psychiatric illness which aetiology remains unknown. Estrogen alpha- and beta-receptors, encoded by ESR1 and ESR2 genes, are involved in food intake regulation and eating behaviour, and may have a potential role in AN. We performed a family-based association study of 17 single-nucleotide polymorphisms (SNPs) encompassing ESR1 and ESR2 genes in a cohort of 321 French AN families. We attempted to replicate this finding in a cohort of 41 RAN families and in a population-based study of 693 young women. Using the transmission disequilibrium test, a significant over-transmission was detected between AN and ESR1 rs726281 and rs2295193. These SNPs and another among ESR1 were more specifically associated with the restrictive AN subtype (RAN) (rs726281, p=0.005, odds ratio [OR]=2.1, 95% Confidence Interval [95%CI]=1.2-3.6; rs3798577, p=0.021, OR=1.6, 95%CI=1.1-2.3; and rs2295193, p=0.007, OR=1.7, 95%CI=1.2-2.5). A large 8-SNPs haplotype of ESR1 gene was also associated with AN (p
Published: 2010
Full Text: View/download PDF

13. Agoraphobie et espace de représentation : une approche comportementale et cognitive

Author: Arnaud Plagnol, Christine Mirabel-Sarron, Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Laboratoire de Psychopathologie et Neuropsychologie [saint-Denis] ( LPN ), Université Paris 8 Vincennes-Saint-Denis ( UP8 ), Institut d'Histoire et de Philosophie des Sciences et des Techniques ( IHPST ), Université Panthéon-Sorbonne ( UP1 ) -Département d'Etudes Cognitives - ENS Paris ( DEC ), École normale supérieure - Paris ( ENS Paris ) -École normale supérieure - Paris ( ENS Paris ) -Centre National de la Recherche Scientifique ( CNRS ), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Institut d'Histoire et de Philosophie des Sciences et des Techniques (IHPST), Université Paris 1 Panthéon-Sorbonne (UP1)-Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Psychopathologie et Neuropsychologie (LPN), Université Paris 8 Vincennes-Saint-Denis (UP8), Université Panthéon-Sorbonne (UP1)-Centre National de la Recherche Scientifique (CNRS)-Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris), and Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5)
Subjects: Phénoménologie, Schémas cognitifs, Panic attacks, Attaques de panique, [ SHS.HISPHILSO ] Humanities and Social Sciences/History, Philosophy and Sociology of Sciences, 030227 psychiatry, 3. Good health, [SHS]Humanities and Social Sciences, [SHS.HISPHILSO]Humanities and Social Sciences/History, Philosophy and Sociology of Sciences, 03 medical and health sciences, Psychiatry and Mental health, Cognitive-behaviour therapy, 0302 clinical medicine, Integrative therapy, Arts and Humanities (miscellaneous), Agoraphobie, 030212 general & internal medicine, Thérapie comportementale et cognitive, Agoraphobia, Applied Psychology, ComputingMilieux_MISCELLANEOUS
Abstract: International audience; Patients suffering of agoraphobia with panic attacks are greatly impaired on their own and interpersonal functioning. In this paper, we described a cognitive and behaviour therapy and his follow-up during five years. We would like to describe that an integrative point of view (gazing clinical, cognitive and behaviour an phenomenological aspects) is relevant to conduct psychotherapy.; L'agoraphobie associée aux attaques de panique est un trouble invalidant aux multiples conséquences personnelles, familiales et sociales. Nous vous présentons dans cet article le suivi thérapeutique pendant cinq années d'un patient agoraphobe, qui a bénéficié d'une approche thérapeutique comportementale et cognitive. Nous avons souhaité montrer qu'un triple regard sur les changements opérés pendant la thérapie - regards cliniques, comportemental, cognitif et phénoménologique - avait permis d'orienter plus justement la thérapie.
Published: 2010
Full Text: View/download PDF

14. Lower leptin level at discharge in acute anorexia nervosa is associated with early weight‐loss

Author: Philip Gorwood, Nebal Alanbar, Philibert Duriez, Jacques Epelbaum, Dominique Grouselle, Roland Dardennes, Virginie Tolle, Nicolas Ramoz, Guillaume Lavoisy, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Université de Paris - UFR Médecine Paris Centre [Santé] (UP Médecine Paris Centre), Université de Paris (UP), Mécanismes Adaptatifs et Evolution (MECADEV), and Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Leptin, 050103 clinical psychology, medicine.medical_specialty, Anorexia Nervosa, [SDV]Life Sciences [q-bio], Aftercare, Gastroenterology, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Weight loss, Internal medicine, Weight Loss, medicine, Humans, 0501 psychology and cognitive sciences, Risk factor, ComputingMilieux_MISCELLANEOUS, 2. Zero hunger, business.industry, digestive, oral, and skin physiology, 05 social sciences, Obestatin, Patient Discharge, 030227 psychiatry, Psychiatry and Mental health, Clinical Psychology, Anorexia nervosa (differential diagnoses), Biomarker (medicine), Ghrelin, medicine.symptom, business, Body mass index, hormones, hormone substitutes, and hormone antagonists
Abstract: OBJECTIVE Predictive values of acute phase metabolic abnormalities of anorexia nervosa (AN) have seldom been studied. As early postrestoration weight loss is associated with poor outcome, discharge biologic parameters were assessed to detect an association with 2-month follow-up weight loss as a proxy to poor outcome. METHOD Fasting plasma levels of leptin, acyl-ghrelin, obestatin, PYY, oxytocin and BDNF were measured in 26 inpatients, at inclusion, at discharge and 2 months later. A body mass index less than 18 2-month postdischarge was considered a poor outcome. RESULTS Nineteen patients (73%) had a fair outcome and seven (27%) had a poor one with a mean loss of 0.69 versus 4.54 kg, respectively. Only discharge leptin levels were significantly higher in fair versus poor outcome patients (14.1 vs. 7.0 ng/ml, p = 0.006). The logistic regression model using discharge leptin, acyl-ghrelin, obestatin, oxytocin, PYY and BDNF levels as predictors of outcome disclosed a nearly significant effect of leptin (p
Published: 2021
Full Text: View/download PDF

15. Espace phobique et levier thérapeutique

Author: Arnaud Plagnol, Christine Mirabel-Sarron, Institut d'Histoire et de Philosophie des Sciences et des Techniques ( IHPST ), Université Panthéon-Sorbonne ( UP1 ) -Département d'Etudes Cognitives - ENS Paris ( DEC ), École normale supérieure - Paris ( ENS Paris ) -École normale supérieure - Paris ( ENS Paris ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Psychopathologie et Neuropsychologie [saint-Denis] ( LPN ), Université Paris 8 Vincennes-Saint-Denis ( UP8 ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Institut d'Histoire et de Philosophie des Sciences et des Techniques (IHPST), Université Paris 1 Panthéon-Sorbonne (UP1)-Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Laboratoire de Psychopathologie et Neuropsychologie (LPN), Université Paris 8 Vincennes-Saint-Denis (UP8), Université Panthéon-Sorbonne (UP1)-Centre National de la Recherche Scientifique (CNRS)-Département d'Etudes Cognitives - ENS Paris (DEC), and École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris)
Subjects: 050103 clinical psychology, Phobia, ESPACE, Représentation, 05 social sciences, Space, Schémas, Cognitive therapy, 050105 experimental psychology, [SHS]Humanities and Social Sciences, [SHS.HISPHILSO]Humanities and Social Sciences/History, Philosophy and Sociology of Sciences, Psychiatry and Mental health, Arts and Humanities (miscellaneous), Thérapies cognitives, Espace, Therapie cognitive, Political science, Phobie, 0501 psychology and cognitive sciences, Humanities, Applied Psychology, ComputingMilieux_MISCELLANEOUS
Abstract: International audience; Introduction : The spatial experience in phobic disorders needs to be better understood in order to account for the pathogenic effect of a local phobogenic situation on the whole subjective world. Such an understanding could be useful for the treatment of resistant phobias which are hampered by therapeutic blocks that require a global restructuration of the subjective world. Objectives : Three objectives are addressed in this paper: (1) a clarification of the experience of space in phobic disorders; (2) an account of the impact power of the phobogenic situation; (3) an analysis of levers in cognitive psychotherapy that may help to overcome therapeutic blocks in resistant phobias. To tackle these objectives, we bring in the conceptual framework of representational spaces that proposes some tools to describe a subjective world as grounded in the spatial experience. According to the model of phobic disorders that we build up in this framework, the phobogenic situation behaves like a probe that reveals some strains disturbing in depth the subjective representational space. These strains depend on past traumatic situations that have resulted in the development of phobic cores. Thus, the phobogenic situation materializes some dimensions of the representational space that makes it vulnerable to a traumatic agent. In this framework, a therapeutic lever can be defined as a key-situation that favors a global reorganization of the representational space from a local work on it. Three conditions appear to be necessary to the works of such a lever: (1) the key-situation needs to resonate through the representational space with a central phobic core; (2) the patient should actively grasp the processes of the symbolic structuration of his/her space; (3) the therapeutic lever should only be operated at the suitable time of the therapeutic course by taking account of the subjective defences. Patient and method : Our model is exemplified with a case study that describes the behavioral and cognitive therapy of a patient that suffers from a phobic disorder since his adolescence. The technical method notably uses a work on the cognitive schemas that starts from the patient story. Results : The method used to overcome therapeutic blocks reveals some phobic cores that are related to traumatic situations in childhood and adolescence. Therapeutic levers are operated when key-situations relative to the familial story can be addressed and elaborated by an active work of the patient, with a feeling of global restructuration of his psychic space. Conclusions : The conceptual framework of the representational spaces is interesting to clarify the spatial experience in phobic disorders and to explain the impact of the phobogenic situation. Moreover, in complex phobias, this framework offers some useful tools to conceptualize the therapeutic levers that could be efficient to move the whole subjective world. Such levels can only be used during a long-term therapy. Introduction : The spatial experience in phobic disorders needs to be better understood in order to account for the pathogenic effect of a local phobogenic situation on the whole subjective world. Such an understanding could be useful for the treatment of resistant phobias which are hampered by therapeutic blocks that require a global restructuration of the subjective world. Objectives : Three objectives are addressed in this paper: (1) a clarification of the experience of space in phobic disorders; (2) an account of the impact power of the phobogenic situation; (3) an analysis of levers in cognitive psychotherapy that may help to overcome therapeutic blocks in resistant phobias. To tackle these objectives, we bring in the conceptual framework of representational spaces that proposes some tools to describe a subjective world as grounded in the spatial experience. According to the model of phobic disorders that we build up in this framework, the phobogenic situation behaves like a probe that reveals some strains disturbing in depth the subjective representational space. These strains depend on past traumatic situations that have resulted in the development of phobic cores. Thus, the phobogenic situation materializes some dimensions of the representational space that makes it vulnerable to a traumatic agent. In this framework, a therapeutic lever can be defined as a key-situation that favors a global reorganization of the representational space from a local work on it. Three conditions appear to be necessary to the works of such a lever: (1) the key-situation needs to resonate through the representational space with a central phobic core; (2) the patient should actively grasp the processes of the symbolic structuration of his/her space; (3) the therapeutic lever should only be operated at the suitable time of the therapeutic course by taking account of the subjective defences. Patient and method : Our model is exemplified with a case study that describes the behavioral and cognitive therapy of a patient that suffers from a phobic disorder since his adolescence. The technical method notably uses a work on the cognitive schemas that starts from the patient story. Results : The method used to overcome therapeutic blocks reveals some phobic cores that are related to traumatic situations in childhood and adolescence. Therapeutic levers are operated when key-situations relative to the familial story can be addressed and elaborated by an active work of the patient, with a feeling of global restructuration of his psychic space. Conclusions : The conceptual framework of the representational spaces is interesting to clarify the spatial experience in phobic disorders and to explain the impact of the phobogenic situation. Moreover, in complex phobias, this framework offers some useful tools to conceptualize the therapeutic levers that could be efficient to move the whole subjective world. Such levels can only be used during a long-term therapy. Introduction : The spatial experience in phobic disorders needs to be better understood in order to account for the pathogenic effect of a local phobogenic situation on the whole subjective world. Such an understanding could be useful for the treatment of resistant phobias which are hampered by therapeutic blocks that require a global restructuration of the subjective world. Objectives : Three objectives are addressed in this paper: (1) a clarification of the experience of space in phobic disorders; (2) an account of the impact power of the phobogenic situation; (3) an analysis of levers in cognitive psychotherapy that may help to overcome therapeutic blocks in resistant phobias. To tackle these objectives, we bring in the conceptual framework of representational spaces that proposes some tools to describe a subjective world as grounded in the spatial experience. According to the model of phobic disorders that we build up in this framework, the phobogenic situation behaves like a probe that reveals some strains disturbing in depth the subjective representational space. These strains depend on past traumatic situations that have resulted in the development of phobic cores. Thus, the phobogenic situation materializes some dimensions of the representational space that makes it vulnerable to a traumatic agent. In this framework, a therapeutic lever can be defined as a key-situation that favors a global reorganization of the representational space from a local work on it. Three conditions appear to be necessary to the works of such a lever: (1) the key-situation needs to resonate through the representational space with a central phobic core; (2) the patient should actively grasp the processes of the symbolic structuration of his/her space; (3) the therapeutic lever should only be operated at the suitable time of the therapeutic course by taking account of the subjective defences. Patient and method : Our model is exemplified with a case study that describes the behavioral and cognitive therapy of a patient that suffers from a phobic disorder since his adolescence. The technical method notably uses a work on the cognitive schemas that starts from the patient story. Results : The method used to overcome therapeutic blocks reveals some phobic cores that are related to traumatic situations in childhood and adolescence. Therapeutic levers are operated when key-situations relative to the familial story can be addressed and elaborated by an active work of the patient, with a feeling of global restructuration of his psychic space. Conclusions : The conceptual framework of the representational spaces is interesting to clarify the spatial experience in phobic disorders and to explain the impact of the phobogenic situation. Moreover, in complex phobias, this framework offers some useful tools to conceptualize the therapeutic levers that could be efficient to move the whole subjective world. Such levels can only be used during a long-term therapy.; Dans cet article, nous visons à éclairer le rôle de l'expérience de l'espace dans les troubles phobiques et à rendre compte de la puissance d'impact de la situation phobogène : malgré son caractère local, celle-ci retentit sur l'ensemble du monde subjectif. À cette fin, nous présentons un cadre conceptuel, celui des espaces de représentation, qui propose des outils pour décrire un monde subjectif en tant que s'enracinant dans l'expérience de l'espace. Nous développons un modèle des troubles phobiques dans ce cadre et nous montrons que la situation phobogène, reflet des tensions issues de l'histoire singulière, matérialise les principales dimensions de vulnérabilité du monde subjectif. Un tel cadre permet notamment d'aborder l'analyse des blocages thérapeutiques dans les phobies résistantes et des leviers qui permettent de surmonter ces blocages dans la perspective des thérapies cognitives. Nous présentons une étude de cas illustrant la pertinence des notions introduites.
Published: 2009
Full Text: View/download PDF

16. Prevalence of mental disorders in French prisons for men

Author: Christiane de Beaurepaire, Bruno Falissard, Frédéric Rouillon, Isabelle Gasquet, Jean-Yves Loze, Anne Duburc, Francis Fagnani, Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de santé publique, évaluation et information médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, BRISTOL-MYERS SQUIBB, CEMKA-EVAL, Service médico-psychologique régional, Prison de Fresne, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, This study has been funded by the French ministries of Health and Justice., Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse, Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, and Autard, Delphine
Subjects: Adult, Male, medicine.medical_specialty, Substance-Related Disorders, lcsh:RC435-571, media_common.quotation_subject, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Prevalence, Prison, Context (language use), Sampling Studies, 03 medical and health sciences, 0302 clinical medicine, Prevalence of mental disorders, Sex Factors, lcsh:Psychiatry, medicine, Humans, 030212 general & internal medicine, Medical diagnosis, Psychiatry, media_common, Psychiatric Status Rating Scales, Depressive Disorder, Major, High prevalence, Mental Disorders, Prisoners, Reproducibility of Results, Middle Aged, medicine.disease, Anxiety Disorders, 030227 psychiatry, 3. Good health, Diagnostic and Statistical Manual of Mental Disorders, Psychiatry and Mental health, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Major depressive disorder, France, Psychology, Research Article
Abstract: Background Psychiatric surveys conducted in prison populations find high prevalence rates, but diagnoses may be difficult in this particular context. None of these surveys have been conducted in France. Methods 800 incarcerated male were sampled at random. Each prisoner was interviewed by a group of 2 clinicians, at least one of them being a senior psychiatrist. One of the clinicians used a structured clinical interview which generated DSM IV diagnosis (MINI plus); the second completed the procedure with an open clinical interview. Results Prevalence rates for a diagnosis given independently by both clinicians and for a consensual diagnosis were respectively: 3.8% (6.2%) for schizophrenia, 17.9% (24%) for major depressive disorder, 12.0% (17.7%) for generalized anxiety and 10.8% (14.6%) for drug dependence. Conclusion Psychiatric diagnosis can be difficult to interpret in prison, especially using traditional standardized interviews. The approach proposed here, with good reliability and closer to a day-to-day clinical practice, yields high prevalence rates.
Published: 2006
Full Text: View/download PDF

17. Approche GABAergique de la dépression du post-partum : une revue critique translationnelle

Author: Caroline Dubertret, P. Duriez, F. Bonnet-Brilhault, Wissam El-Hage, J. Verbe, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), CCSD, Accord Elsevier, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), and GHU Paris Psychiatrie et Neurosciences
Subjects: [SDV]Life Sciences [q-bio], Neurostéroïdes, Allopregnanolone, Dépression du post-partum, 3. Good health, 030227 psychiatry, [SDV] Life Sciences [q-bio], GABA, 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, Arts and Humanities (miscellaneous), Postpartum depression, Neurosteroid, Brexanolone
Abstract: International audience; Introduction: Prevalence of postpartum depression (PPD) ranges from 10 to 15 % of parturients. The impact of the PPD is major on the maternal bond and the health of both mother and child. Its physiopathological mechanisms appear to differ from other types of depression. Today, pharmacotherapy is based on nonspecific treatment, and recent therapeutic advances in this field require a comprehensive approach of the implication of the GABAergic system in the development of PPD. Neurosteroid levels during pregnancy and after parturition and the GABA-A-r modulation are thought to be involved in PPD.Objective: To evaluate if the GABAergic approach is relevant in postpartum depression management.Methods: We conducted a systematic review of literature based on the MEDLINE database with the following Medical Subject Headings (MeSH): "postpartum depression", "GABA", "ganaxolone", "brexanolone", "allopregnanolone", prior to September 2019. We selected articles in English: preclinical and clinical studies, literature review, observational and therapeutic studies.Results: Preclinical models (mouse and rat) show changes in GABAergic inhibition in the peripartum period and correlation between allopregnanolone and GABA-A-r plasticity. This plasticity in the peripartum period maintains levels of inhibition adapted despite increased neurosteroid levels. KO models for the GABA-A-r δ subunit develop depression and anxiety symptoms in the postpartum period, and a change in the expression of the gene coding for the GABA-R alpha-4 subunit was found. Artificial inhibition of progesterone metabolism during post-partum increased depression symptoms. GABAergic fluctuation seems to be interrelated with other systems such as those of oxytocins. A synthetic neurosteroid (SGE-516) was tested on mouse models of PPD, KO for δ-GABA-A-r or KCC2, and showed decreased depressive symptoms and better mothering. Clinical studies confirm neurosteroid fluctuation and changes in the GABAergic system during the peripartum period. Allopregnanolone is the neurosteroid the most studied in PPD, and it is elevated in the brain during the pregnancy. Studies disagree on the presence of significant differences in allopregnanolone plasma levels during pregnancy or postpartum between women with PPD or not. Women with a history of PPD have greater susceptibility to neurosteroid withdrawal. Imagery and genetical data also show a link between allopregnanolone and PPD. The GABA-A-r may not recover in time following a reduced number during pregnancy, and this mismatch between neurosteroid levels and their receptor may trigger PPD. Several randomized controlled trials investigated brexanolone administrated IV, a synthetic formulation of allopregnanolone, and demonstrated a rapid and well tolerated reduction in depressive symptoms. In March 2019 brexanolone obtained FDA approval in PPD indication under the name Zulresso. However, there are differences in the time of beginning of PPD, which could constitute different subgroups of this disease, and which physiopathology could respond to different mechanisms. Prenatal depression does not respond to a GABAergic approach, but women without any risk factor or previous mood disorder developing PPD in the weeks following childbirth could be particularly responsive to this kind of treatment.Conclusion: Disability to modulate GABA-A-r expression during pregnancy and restore its previous state after parturition appears to trigger PPD. The GABAergic system is a promising pharmacotherapy target. From preclinical to clinical studies for about twenty years the GABAergic system has been incriminated and targeted in this challenging mental disease.
Published: 2020
Full Text: View/download PDF

18. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic

Author: Solmi, Marco, Estradé, Andrés, Thompson, Trevor, Agorastos, Agorastos, Radua, Joaquim, Cortese, Samuele, Dragioti, Elena, Leisch, Friedrich, Vancampfort, Davy, Thygesen, Lau Caspar, Aschauer, Harald, Schloegelhofer, Monika, Akimova, Elena, Schneeberger, Andres, Huber, Christian, Hasler, Gregor, Conus, Philippe, Cuénod, Kim, von Känel, Roland, Arrondo, Gonzalo, Fusar-Poli, Paolo, Gorwood, Philip, Llorca, Pierre-Michel, Krebs, Marie-Odile, Scanferla, Elisabetta, Kishimoto, Taishiro, Rabbani, Golam, Skonieczna-Żydecka, Karolina, Brambilla, Paolo, Favaro, Angela, Takamiya, Akihiro, Zoccante, Leonardo, Colizzi, Marco, Bourgin, Julie, Kamiński, Karol, Moghadasin, Maryam, Seedat, Soraya, Matthews, Evan, Wells, John, Vassilopoulou, Emilia, Gadelha, Ary, Su, Kuan-Pin, Kwon, Jun Soo, Kim, Minah, Lee, Tae Young, Papsuev, Oleg, Manková, Denisa, Boscutti, Andrea, Gerunda, Cristiano, Saccon, Diego, Righi, Elena, Monaco, Francesco, Croatto, Giovanni, Cereda, Guido, Demurtas, Jacopo, Brondino, Natascia, Veronese, Nicola, Enrico, Paolo, Politi, Pierluigi, Ciappolino, Valentina, Pfennig, Andrea, Bechdolf, Andreas, Meyer-Lindenberg, Andreas, Kahl, Kai, Domschke, Katharina, Bauer, Michael, Koutsouleris, Nikolaos, Winter, Sibylle, Borgwardt, Stefan, Bitter, Istvan, Balazs, Judit, Czobor, Pal, Unoka, Zsolt, Mavridis, Dimitris, Tsamakis, Konstantinos, Bozikas, Vasilios, Tunvirachaisakul, Chavit, Maes, Michael, Rungnirundorn, Teerayuth, Supasitthumrong, Thitiporn, Haque, Ariful, Brunoni, Andre, Costardi, Carlos Gustavo, Schuch, Felipe Barreto, Polanczyk, Guilherme, Luiz, Jhoanne Merlyn, Fonseca, Lais, Aparicio, Luana, Valvassori, Samira, Nordentoft, Merete, Vendsborg, Per, Hoffmann, Sofie Have, Sehli, Jihed, Sartorius, Norman, Heuss, Sabina, Guinart, Daniel, Hamilton, Jane, Kane, John, Rubio, Jose, Sand, Michael, Koyanagi, Ai, Solanes, Aleix, Andreu-Bernabeu, Alvaro, Cáceres, Antonia San José, Arango, Celso, Díaz-Caneja, Covadonga, Hidalgo-Mazzei, Diego, Vieta, Eduard, Gonzalez-Peñas, Javier, Fortea, Lydia, Parellada, Mara, Fullana, Miquel, Verdolini, Norma, Fárková, Eva, Janků, Karolina, Millan, Mark, Honciuc, Mihaela, Moniuszko-Malinowska, Anna, Łoniewski, Igor, Samochowiec, Jerzy, Kiszkiel, Łukasz, Marlicz, Maria, Sowa, Paweł, Marlicz, Wojciech, Spies, Georgina, Stubbs, Brendon, Firth, Joseph, Sullivan, Sarah, Darcin, Asli Enez, Aksu, Hatice, Dilbaz, Nesrin, Noyan, Onur, Kitazawa, Momoko, Kurokawa, Shunya, Tazawa, Yuki, Anselmi, Alejandro, Cracco, Cecilia, Machado, Ana Inés, Estrade, Natalia, de Leo, Diego, Curtis, Jackie, Berk, Michael, Ward, Philip, Teasdale, Scott, Rosenbaum, Simon, Marx, Wolfgang, Horodnic, Adrian Vasile, Oprea, Liviu, Alexinschi, Ovidiu, Ifteni, Petru, Turliuc, Serban, Ciuhodaru, Tudor, Bolos, Alexandra, Matei, Valentin, Nieman, Dorien, Sommer, Iris, van Os, Jim, van Amelsvoort, Therese, Sun, Ching-Fang, Guu, Ta-Wei, Jiao, Can, Zhang, Jieting, Fan, Jialin, Zou, Liye, Yu, Xin, Chi, Xinli, de Timary, Philippe, van Winke, Ruud, Ng, Bernardo, Pena, Edilberto, Arellano, Ramon, Roman, Raquel, Sanchez, Thelma, Movina, Larisa, Morgado, Pedro, Brissos, Sofia, Aizberg, Oleg, Mosina, Anna, Krinitski, Damir, Mugisha, James, Sadeghi-Bahmani, Dena, Sadeghi, Masoud, Hadi, Samira, Brand, Serge, Errazuriz, Antonia, Crossley, Nicolas, Ristic, Dragana Ignjatovic, López-Jaramillo, Carlos, Efthymiou, Dimitris, Kuttichira, Praveenlal, Kallivayalil, Roy Abraham, Javed, Afzal, Afridi, Muhammad Iqbal, James, Bawo, Seb-Akahomen, Omonefe Joy, Fiedorowicz, Jess, Carvalho, Andre, Daskalakis, Jeff, Yatham, Lakshmi, Yang, Lin, Okasha, Tarek, Dahdouh, Aïcha, Gerdle, Björn, Tiihonen, Jari, Shin, Jae Il, Lee, Jinhee, Mhalla, Ahmed, Gaha, Lotfi, Brahim, Takoua, Altynbekov, Kuanysh, Negay, Nikolay, Nurmagambetova, Saltanat, Jamei, Yasser Abu, Weiser, Mark, Correll, Christoph, Thygesen, Lau, Kwon, Jun, Lee, Tae, Costardi, Carlos, Schuch, Felipe, Luiz, Jhoanne, Hoffmann, Sofie, Cáceres, Antonia, Darcin, Asli, Machado, Ana, Horodnic, Adrian, Ristic, Dragana, Kallivayalil, Roy, Afridi, Muhammad, Seb-Akahomen, Omonefe, Shin, Jae, Jamei, Yasser, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, MUMC+: MA Med Staf Spec Psychiatrie (9), Clinical Cognitive Neuropsychiatry Research Program (CCNP), Movement Disorder (MD), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), GHU Paris Psychiatrie et Neurosciences, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Clermont-Ferrand, Pathologies et épithéliums : prévention, innovation, traitements, évaluation (UR 4267) (PEPITE), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Martinez Rico, Clara, Solmi, M., Estradé, A., Thompson, T., Agorastos, A., Radua, J., Cortese, S., Dragioti, E., Leisch, F., Vancampfort, D., Thygesen, L.C., Aschauer, H., Schloegelhofer, M., Akimova, E., Schneeberger, A., Huber, C.G., Hasler, G., Conus, P., Cuénod, K.Q.D., von Känel, R., Arrondo, G., Fusar-Poli, P., Gorwood, P., Llorca, P.-M., Krebs, M.-O., Scanferla, E., Kishimoto, T., Rabbani, G., Skonieczna-Żydecka, K., Brambilla, P., Favaro, A., Takamiya, A., Zoccante, L., Colizzi, M., Bourgin, J., Kamiński, K., Moghadasin, M., Seedat, S., Matthews, E., Wells, J., Vassilopoulou, E., Gadelha, A., Su, K.-P., Kwon, J.S., Kim, M., Lee, T.Y., Papsuev, O., Manková, D., Boscutti, A., Gerunda, C., Saccon, D., Righi, E., Monaco, F., Croatto, G., Cereda, G., Demurtas, J., Brondino, N., Veronese, N., Enrico, P., Politi, P., Ciappolino, V., Pfennig, A., Bechdolf, A., Meyer-Lindenberg, A., Kahl, K.G., Domschke, K., Bauer, M., Koutsouleris, N., Winter, S., Borgwardt, S., Bitter, I., Balazs, J., Czobor, P., Unoka, Z., Mavridis, D., Tsamakis, K., Bozikas, V.P., Tunvirachaisakul, C., Maes, M., Rungnirundorn, T., Supasitthumrong, T., Haque, A., Brunoni, A.R., Costardi, C.G., Schuch, F.B., Polanczyk, G., Luiz, J.M., Fonseca, L., Aparicio, L.V., Valvassori, S.S., Nordentoft, M., Vendsborg, P., Hoffmann, S.H., Sehli, J., Sartorius, N., Heuss, S., Guinart, D., Hamilton, J., Kane, J., Rubio, J., Sand, M., Koyanagi, A., Solanes, A., Andreu-Bernabeu, A., Cáceres, A.S.J., Arango, C., Díaz-Caneja, C.M., Hidalgo-Mazzei, D., Vieta, E., Gonzalez-Peñas, J., Fortea, L., Parellada, M., Fullana, M.A., Verdolini, N., Fárková, E., Janků, K., Millan, M., Honciuc, M., Moniuszko-Malinowska, A., Łoniewski, I., Samochowiec, J., Kiszkiel, Ł., Marlicz, M., Sowa, P., Marlicz, W., Spies, G., Stubbs, B., Firth, J., Sullivan, S., Darcin, A.E., Aksu, H., Dilbaz, N., Noyan, O., Kitazawa, M., Kurokawa, S., Tazawa, Y., Anselmi, A., Cracco, C., Machado, A.I., Estrade, N., De Leo, D., Curtis, J., Berk, M., Ward, P., Teasdale, S., Rosenbaum, S., Marx, W., Horodnic, A.V., Oprea, L., Alexinschi, O., Ifteni, P., Turliuc, S., Ciuhodaru, T., Bolos, A., Matei, V., Nieman, D.H., Sommer, I., van Os, J., van Amelsvoort, T., Sun, C.-F., Guu, T.-W., Jiao, C., Zhang, J., Fan, J., Zou, L., Yu, X., Chi, X., de Timary, P., van Winke, R., Ng, B., Pena, E., Arellano, R., Roman, R., Sanchez, T., Movina, L., Morgado, P., Brissos, S., Aizberg, O., Mosina, A., Krinitski, D., Mugisha, J., Sadeghi-Bahmani, D., Sadeghi, M., Hadi, S., Brand, S., Errazuriz, A., Crossley, N., Ristic, D.I., López-Jaramillo, C., Efthymiou, D., Kuttichira, P., Kallivayalil, R.A., Javed, A., Afridi, M.I., James, B., Seb-Akahomen, O.J., Fiedorowicz, J., Carvalho, A.F., Daskalakis, J., Yatham, L.N., Yang, L., Okasha, T., Dahdouh, A., Gerdle, B., Tiihonen, J., Shin, J.I., Lee, J., Mhalla, A., Gaha, L., Brahim, T., Altynbekov, K., Negay, N., Nurmagambetova, S., Jamei, Y.A., Weiser, M., Correll, C.U., Adult Psychiatry, APH - Mental Health, ANS - Compulsivity, Impulsivity & Attention, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep
Subjects: Gerontology, DISORDER, STRESS, Outcome Assessment, IMPACT, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, RA0421, well-being, Pandemic, Health care, Outcome Assessment, Health Care, adults, Medicine, ANXIETY, COVID-19, mental health, functioning, physical health, representative, resilience, survey, international, psychiatry, depression, anxiety, post-traumatic, COH-FIT, children, adolescents, mental health, functioning, physical health, representative, well-being, resilience, survey, international, psychiatry, depression, anxiety, post-traumatic, COH-FIT, children, adolescents, adult, Child, SCALE, Psychiatry, education.field_of_study, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Public Health, Global Health, Social Medicine and Epidemiology, Psychiatry and Mental health, Clinical Psychology, Professional association, Life Sciences & Biomedicine, Psychopathology, Research Paper, Adult, Coronavirus disease 2019 (COVID-19), Adolescent, Population, Clinical Neurology, BF, Anxiety, Cross-Sectional Studies, Depression, Humans, Mental Health, SARS-CoV-2, Pandemics, Intervention (counseling), MANAGEMENT, VALIDITY, education, Science & Technology, business.industry, MORTALITY, CARE, Mental health, Health Care, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Neurosciences & Neurology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: BACKGROUND: . High-quality comprehensive data on short-/long-term physical/mental health effects of the COVID-19 pandemic are needed. METHODS: . The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) is an international, multi-language (n=30) project involving >230 investigators from 49 countries/territories/regions, endorsed by national/international professional associations. COH-FIT is a multi-wave, on-line anonymous, cross-sectional survey [wave 1: 04/2020 until the end of the pandemic, 12 months waves 2/3 starting 6/24 months threreafter] for adults, adolescents (14-17), and children (6-13), utilizing non-probability/snowball and representative sampling. COH-FIT aims to identify non-modifiable/modifiable risk factors/treatment targets to inform prevention/intervention programs to improve social/health outcomes in the general population/vulnerable subgrous during/after COVID-19. In adults, co-primary outcomes are change from pre-COVID-19 to intra-COVID-19 in well-being (WHO-5) and a composite psychopathology P-Score. Key secondary outcomes are a P-extended score, global mental and physical health. Secondary outcomes include health-service utilization/functioning, treatment adherence, functioning, symptoms/behaviors/emotions, substance use, violence, among others. RESULTS: . Starting 04/26/2020, up to 14/07/2021 >151,000 people from 155 countries/territories/regions and six continents have participated. Representative samples of ≥1,000 adults have been collected in 15 countries. Overall, 43.0% had prior physical disorders, 16.3% had prior mental disorders, 26.5% were health care workers, 8.2% were aged ≥65 years, 19.3% were exposed to someone infected with COVID-19, 76.1% had been in quarantine, and 2.1% had been COVID 19-positive. LIMITATIONS: . Cross-sectional survey, preponderance of non-representative participants. CONCLUSIONS: . Results from COH-FIT will comprehensively quantify the impact of COVID-19, seeking to identify high-risk groups in need for acute and long-term intervention, and inform evidence-based health policies/strategies during this/future pandemics. ispartof: JOURNAL OF AFFECTIVE DISORDERS vol:299 pages:393-407 ispartof: location:Netherlands status: published
Published: 2022
Full Text: View/download PDF

19. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times-Children and Adolescents (COH-FIT-C&A)

Author: Solmi, Marco, Estradé, Andrés, Thompson, Trevor, Agorastos, Agorastos, Radua, Joaquim, Cortese, Samuele, Dragioti, Elena, Leisch, Friedrich, Vancampfort, Davy, Thygesen, Lau Caspar, Aschauer, Harald, Schloegelhofer, Monika, Akimova, Elena, Schneeberger, Andres, Huber, Christian, Hasler, Gregor, Conus, Philippe, Cuénod, Kim, von Känel, Roland, Arrondo, Gonzalo, Fusar-Poli, Paolo, Gorwood, Philip, Llorca, Pierre-Michel, Krebs, Marie-Odile, Scanferla, Elisabetta, Kishimoto, Taishiro, Rabbani, Golam, Skonieczna-Żydecka, Karolina, Brambilla, Paolo, Favaro, Angela, Takamiya, Akihiro, Zoccante, Leonardo, Colizzi, Marco, Bourgin, Julie, Kamiński, Karol, Moghadasin, Maryam, Seedat, Soraya, Matthews, Evan, Wells, John, Vassilopoulou, Emilia, Gadelha, Ary, Su, Kuan-Pin, Kwon, Jun Soo, Kim, Minah, Lee, Tae Young, Papsuev, Oleg, Manková, Denisa, Boscutti, Andrea, Gerunda, Cristiano, Saccon, Diego, Righi, Elena, Monaco, Francesco, Croatto, Giovanni, Cereda, Guido, Demurtas, Jacopo, Brondino, Natascia, Veronese, Nicola, Enrico, Paolo, Politi, Pierluigi, Ciappolino, Valentina, Pfennig, Andrea, Bechdolf, Andreas, Meyer-Lindenberg, Andreas, Kahl, Kai, Domschke, Katharina, Bauer, Michael, Koutsouleris, Nikolaos, Winter, Sibylle, Borgwardt, Stefan, Bitter, Istvan, Balazs, Judit, Czobor, Pal, Unoka, Zsolt, Mavridis, Dimitris, Tsamakis, Konstantinos, Bozikas, Vasilios, Tunvirachaisakul, Chavit, Maes, Michael, Rungnirundorn, Teerayuth, Supasitthumrong, Thitiporn, Haque, Ariful, Brunoni, Andre, Costardi, Carlos Gustavo, Schuch, Felipe Barreto, Polanczyk, Guilherme, Luiz, Jhoanne Merlyn, Fonseca, Lais, Aparicio, Luana, Valvassori, Samira, Nordentoft, Merete, Vendsborg, Per, Hoffmann, Sofie Have, Sehli, Jihed, Sartorius, Norman, Heuss, Sabina, Guinart, Daniel, Hamilton, Jane, Kane, John, Rubio, Jose, Sand, Michael, Koyanagi, Ai, Solanes, Aleix, Andreu-Bernabeu, Alvaro, Cáceres, Antonia San José, Arango, Celso, Díaz-Caneja, Covadonga, Hidalgo-Mazzei, Diego, Vieta, Eduard, Gonzalez-Peñas, Javier, Fortea, Lydia, Parellada, Mara, Fullana, Miquel, Verdolini, Norma, Fárková, Eva, Janků, Karolina, Millan, Mark, Honciuc, Mihaela, Moniuszko-Malinowska, Anna, Łoniewski, Igor, Samochowiec, Jerzy, Kiszkiel, Łukasz, Marlicz, Maria, Sowa, Paweł, Marlicz, Wojciech, Spies, Georgina, Stubbs, Brendon, Firth, Joseph, Sullivan, Sarah, Darcin, Asli Enez, Aksu, Hatice, Dilbaz, Nesrin, Noyan, Onur, Kitazawa, Momoko, Kurokawa, Shunya, Tazawa, Yuki, Anselmi, Alejandro, Cracco, Cecilia, Machado, Ana Inés, Estrade, Natalia, de Leo, Diego, Curtis, Jackie, Berk, Michael, Ward, Philip, Teasdale, Scott, Rosenbaum, Simon, Marx, Wolfgang, Horodnic, Adrian Vasile, Oprea, Liviu, Alexinschi, Ovidiu, Ifteni, Petru, Turliuc, Serban, Ciuhodaru, Tudor, Bolos, Alexandra, Matei, Valentin, Nieman, Dorien, Sommer, Iris, van Os, Jim, van Amelsvoort, Therese, Sun, Ching-Fang, Guu, Ta-Wei, Jiao, Can, Zhang, Jieting, Fan, Jialin, Zou, Liye, Yu, Xin, Chi, Xinli, de Timary, Philippe, van Winke, Ruud, Ng, Bernardo, Pena, Edilberto, Arellano, Ramon, Roman, Raquel, Sanchez, Thelma, Movina, Larisa, Morgado, Pedro, Brissos, Sofia, Aizberg, Oleg, Mosina, Anna, Krinitski, Damir, Mugisha, James, Sadeghi-Bahmani, Dena, Sadeghi, Masoud, Hadi, Samira, Brand, Serge, Errazuriz, Antonia, Crossley, Nicolas, Ristic, Dragana Ignjatovic, López-Jaramillo, Carlos, Efthymiou, Dimitris, Kuttichira, Praveenlal, Kallivayalil, Roy Abraham, Javed, Afzal, Afridi, Muhammad Iqbal, James, Bawo, Seb-Akahomen, Omonefe Joy, Fiedorowicz, Jess, Carvalho, Andre, Daskalakis, Jeff, Yatham, Lakshmi, Yang, Lin, Okasha, Tarek, Dahdouh, Aïcha, Gerdle, Björn, Tiihonen, Jari, Shin, Jae Il, Lee, Jinhee, Mhalla, Ahmed, Gaha, Lotfi, Brahim, Takoua, Altynbekov, Kuanysh, Negay, Nikolay, Nurmagambetova, Saltanat, Jamei, Yasser Abu, Weiser, Mark, Correll, Christoph, Thygesen, Lau, Kwon, Jun, Lee, Tae, Costardi, Carlos, Schuch, Felipe, Luiz, Jhoanne, Hoffmann, Sofie, Cáceres, Antonia, Darcin, Asli, Machado, Ana, Horodnic, Adrian, Ristic, Dragana, Kallivayalil, Roy, Afridi, Muhammad, Seb-Akahomen, Omonefe, Shin, Jae, Jamei, Yasser, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, MUMC+: MA Med Staf Spec Psychiatrie (9), Clinical Cognitive Neuropsychiatry Research Program (CCNP), Movement Disorder (MD), Solmi, M., Estradé, A., Thompson, T., Agorastos, A., Radua, J., Cortese, S., Dragioti, E., Leisch, F., Vancampfort, D., Thygesen, L.C., Aschauer, H., Schloegelhofer, M., Akimova, E., Schneeberger, A., Huber, C.G., Hasler, G., Conus, P., Cuénod, K.Q.D., von Känel, R., Arrondo, G., Fusar-Poli, P., Gorwood, P., Llorca, P.-M., Krebs, M.-O., Scanferla, E., Kishimoto, T., Rabbani, G., Skonieczna-Żydecka, K., Brambilla, P., Favaro, A., Takamiya, A., Zoccante, L., Colizzi, M., Bourgin, J., Kamiński, K., Moghadasin, M., Seedat, S., Matthews, E., Wells, J., Vassilopoulou, E., Gadelha, A., Su, K.-P., Kwon, J.S., Kim, M., Lee, T.Y., Papsuev, O., Manková, D., Boscutti, A., Gerunda, C., Saccon, D., Righi, E., Monaco, F., Croatto, G., Cereda, G., Demurtas, J., Brondino, N., Veronese, N., Enrico, P., Politi, P., Ciappolino, V., Pfennig, A., Bechdolf, A., Meyer-Lindenberg, A., Kahl, K.G., Domschke, K., Bauer, M., Koutsouleris, N., Winter, S., Borgwardt, S., Bitter, I., Balazs, J., Czobor, P., Unoka, Z., Mavridis, D., Tsamakis, K., Bozikas, V.P., Tunvirachaisakul, C., Maes, M., Rungnirundorn, T., Supasitthumrong, T., Haque, A., Brunoni, A.R., Costardi, C.G., Schuch, F.B., Polanczyk, G., Luiz, J.M., Fonseca, L., Aparicio, L.V., Valvassori, S.S., Nordentoft, M., Vendsborg, P., Hoffmann, S.H., Sehli, J., Sartorius, N., Heuss, S., Guinart, D., Hamilton, J., Kane, J., Rubio, J., Sand, M., Koyanagi, A., Solanes, A., Andreu-Bernabeu, A., Cáceres, A.S.J., Arango, C., Díaz-Caneja, C.M., Hidalgo-Mazzei, D., Vieta, E., Gonzalez-Peñas, J., Fortea, L., Parellada, M., Fullana, M.A., Verdolini, N., Fárková, E., Janků, K., Millan, M., Honciuc, M., Moniuszko-Malinowska, A., Łoniewski, I., Samochowiec, J., Kiszkiel, Ł., Marlicz, M., Sowa, P., Marlicz, W., Spies, G., Stubbs, B., Firth, J., Sullivan, S., Darcin, A.E., Aksu, H., Dilbaz, N., Noyan, O., Kitazawa, M., Kurokawa, S., Tazawa, Y., Anselmi, A., Cracco, C., Machado, A.I., Estrade, N., De Leo, D., Curtis, J., Berk, M., Ward, P., Teasdale, S., Rosenbaum, S., Marx, W., Horodnic, A.V., Oprea, L., Alexinschi, O., Ifteni, P., Turliuc, S., Ciuhodaru, T., Bolos, A., Matei, V., Nieman, D.H., Sommer, I., van Os, J., van Amelsvoort, T., Sun, C.-F., Guu, T.-W., Jiao, C., Zhang, J., Fan, J., Zou, L., Yu, X., Chi, X., de Timary, P., van Winke, R., Ng, B., Pena, E., Arellano, R., Roman, R., Sanchez, T., Movina, L., Morgado, P., Brissos, S., Aizberg, O., Mosina, A., Krinitski, D., Mugisha, J., Sadeghi-Bahmani, D., Sadeghi, M., Hadi, S., Brand, S., Errazuriz, A., Crossley, N., Ristic, D.I., López-Jaramillo, C., Efthymiou, D., Kuttichira, P., Kallivayalil, R.A., Javed, A., Afridi, M.I., James, B., Seb-Akahomen, O.J., Fiedorowicz, J., Carvalho, A.F., Daskalakis, J., Yatham, L.N., Yang, L., Okasha, T., Dahdouh, A., Gerdle, B., Tiihonen, J., Shin, J.I., Lee, J., Mhalla, A., Gaha, L., Brahim, T., Altynbekov, K., Negay, N., Nurmagambetova, S., Jamei, Y.A., Weiser, M., Correll, C.U., Adult Psychiatry, APH - Mental Health, ANS - Compulsivity, Impulsivity & Attention, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Martinez Rico, Clara, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), GHU Paris Psychiatrie et Neurosciences, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Clermont-Ferrand, Pathologies et épithéliums : prévention, innovation, traitements, évaluation (UR 4267) (PEPITE), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)
Subjects: Gerontology, DISORDER, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Psychological intervention, Physical health, Adolescents, HV, Children, Covid-19, Mental health, Pandemic, Resilience, RA0421, Medicine, Adolescent, Adult, Child, Cross-Sectional Studies, Health Promotion, Humans, Mental Health, Pandemics, Quality of Life, SARS-CoV-2, COVID-19, SCALE, media_common, Psychiatry, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Public Health, Global Health, Social Medicine and Epidemiology, Psychiatry and Mental health, Clinical Psychology, Professional association, Psychological resilience, Life Sciences & Biomedicine, Psychopathology, Covid-19, Pandemic, Mental health, Physical health, Resilience, Children, Adolescents, media_common.quotation_subject, Clinical Neurology, BF, Article, Quality of life (healthcare), Intervention (counseling), VALIDITY, Science & Technology, business.industry, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Neurosciences & Neurology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: BACKGROUND: The COVID-19 pandemic has altered daily routines and family functioning, led to closing schools, and dramatically limited social interactions worldwide. Measuring its impact on mental health of vulnerable children and adolescents is crucial. METHODS: The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT - www.coh-fit.com) is an on-line anonymous survey, available in 30 languages, involving >230 investigators from 49 countries supported by national/international professional associations. COH-FIT has thee waves (until the pandemic is declared over by the WHO, and 6-18 months plus 24-36 months after its end). In addition to adults, COH-FIT also includes adolescents (age 14-17 years), and children (age 6-13 years), recruited via non-probability/snowball and representative sampling and assessed via self-rating and parental rating. Non-modifiable/modifiable risk factors/treatment targets to inform prevention/intervention programs to promote health and prevent mental and physical illness in children and adolescents will be generated by COH-FIT. Co-primary outcomes are changes in well-being (WHO-5) and a composite psychopathology P-Score. Multiple behavioral, family, coping strategy and service utilization factors are also assessed, including functioning and quality of life. RESULTS: Up to June 2021, over 13,000 children and adolescents from 59 countries have participated in the COH-FIT project, with representative samples from eleven countries. LIMITATIONS: Cross-sectional and anonymous design. CONCLUSIONS: Evidence generated by COH-FIT will provide an international estimate of the COVID-19 effect on children's, adolescents' and families', mental and physical health, well-being, functioning and quality of life, informing the formulation of present and future evidence-based interventions and policies to minimize adverse effects of the present and future pandemics on youth. ispartof: JOURNAL OF AFFECTIVE DISORDERS vol:299 pages:367-376 ispartof: location:Netherlands status: published
Published: 2022
Full Text: View/download PDF

20. Cannabis : quels effets sur le comportement et la santé ?

Author: Aquatias, Sylvain, Arditti, Jocelyne, Bailly, Isabelle, Biecheler, Marie-Berthe, Bouaboula, Monsif, Coqus, Jean-Claude, Grémy, Isabelle, Laqueille, Xavier, Maldonado, Rafael, Mallaret, Michel, Manzoni, Olivier, Mura, Patrick, Reynaud, Michel, Venance, Laurent, Centre antipoison et de toxicovigilance (Marseille) (CAPTV Marseille), Assistance Publique - Hôpitaux de Marseille (APHM), Institut National de Recherche sur les Transports et leur Sécurité (INRETS), Département immunologie-oncologie, Sanofi-Synthélabo, GET T51 médecine générale et conduites addictives, Observatoire régional de santé Ile-de-France HIV/sida (ORS), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Universitat Pompeu Fabra [Barcelona] (UPF), Centre régional de pharmacovigilance, Centre Hospitalier Universitaire [Grenoble] (CHU), Mécanismes moléculaires des communications cellulaires, Centre National de la Recherche Scientifique (CNRS)-Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2), Hôpital Jean Bernard, Service de psychiatrie et addictologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Chaire Neuropharmacologie (INSERM U114), Collège de France (CdF (institution)), Institut national de la santé et de la recherche médicale(INSERM), Centre antipoison, hopital salvador, Institut National de Recherche sur les Transports et leur Sécurité ( INRETS ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Universitat Pompeu Fabra [Barcelona], Centre Hospitalier Universitaire [Grenoble] ( CHU ), Mécanismes moléculaires des communications, Centre National de la Recherche Scientifique ( CNRS ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse, Neurobiologie pharmacologique, Collège de France ( CdF ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Collège de France - Chaire Neuropharmacologie (INSERM U114), and ORANGE, Colette
Subjects: Produits psychoactifs, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Drogues, Dépendance, Haschich, Herbe, Sevrage, Cannabis sativa indica, Troubles de l'humeur, Chanvre indien, Cannabinoïdes
Abstract: Les données épidémiologiques recueillies en Europe comme aux États-Unis,en Australie ou en Nouvelle-Zélande mettent en évidence une augmentationde la prévalence d’usage de cannabis dans les populations jeunes.Alors que les travaux de recherche fondamentale sur les cannabinoïdes ontfait un bond considérable durant les dernières années, force est de constater leslacunes dans la connaissance sur les effets sur la santé de l’usage de cannabis.Fondées sur des observations, des études cliniques ou au mieux sur des étudesrétrospectives, les données sur les différents effets aigus et chroniques ducannabis sont encore peu nombreuses ou contradictoires. Il faut noter d’embléela difficulté à recueillir des données dans les populations vis-à-vis d’unproduit illicite.La Mission interministérielle de lutte contre la drogue et la toxicomanie(MILDT) a souhaité disposer d’un bilan des connaissances disponibles sur leseffets sur le comportement et la santé de l’usage de cannabis, à partir d’uneanalyse exhaustive de la littérature, et a demandé à l’Inserm de conduire cetravail à travers la procédure d’expertise collective.Pour répondre à cette demande, l’Inserm a réuni un groupe pluridisciplinaired’experts scientifiques dans les domaines de l’épidémiologie descriptive etanalytique, de la sociologie, de la biologie et de la neurobiologie, de latoxicologie, de la neuropharmacologie et de la clinique (psychiatres cliniciensou généraliste).Le groupe d’experts a structuré son analyse à partir des questions suivantes :• Que sait-on des niveaux de consommation de cannabis, de leur évolutiondans le temps et des caractéristiques des consommateurs, notamment chez lesjeunes ? Les évolutions décrites en France sont-elles comparables à cellesobservées dans les autres pays développés ?• Que sait-on des contextes et des modes de consommations : situationsd’expérimentation du produit, proportion et caractéristiques des consommateursréguliers, importance des phénomènes de polyconsommation, trajectoiresde consommation ? Que sait-on de l’évolution de l’offre de cannabis et desfilières de distribution dans différents milieux sociaux ? Quel est le lien entreconsommation et désocialisation ou délinquance ?• Quels sont les caractéristiques du produit ? Quels sont les principes actifsselon les différentes variétés de cannabis ? Quel est le métabolisme du cannabischez l’homme ? Quels sont les marqueurs biologiques de la présence decannabis dans l’organisme ?• Quels sont les effets du cannabis sur la santé ? Quels sont les effets neurologiques? Sont-ils réversibles ? Le cannabis induit-il une dépendance ? Que sait-on des interactions avec d’autres produits ? Quel est le lien entre consommationde cannabis et troubles psychiatriques ?• Quels sont les autres effets sur la santé, en particulier sur les systèmesrespiratoire, cardiovasculaire et immunitaire, ainsi que sur la fertilité et lafécondité ? Quelles sont les données sur l’effet cancérogène potentiel ?• Quels sont les résultats des études menées chez l’animal ? Dans quellemesure peuvent-elles éclairer les données recueillies chez l’homme ?• Quels sont les mécanismes d’action des cannabinoïdes sur les différentstissus cibles ?L’interrogation des bases Medline, Embase, Toxibase, Psycinfo et Pascal aconduit à sélectionner environ 1 200 articles. Une majorité de publicationsconcerne les mécanismes d’action du principe actif du cannabis, le D9-THC,en relation avec le système endocannabinoïde. Une partie des études menéeschez l’animal sont déjà anciennes et une attention particulière à été portéeaux travaux récents les plus rigoureux. Quant aux données chez l’homme,l’ensemble des travaux (rapports de cas, études cas-témoins, études rétrospectives{)a été pris en considération ainsi que les divers rapports accessibles surle sujet.Au cours de huit séances de travail organisées entre les mois d’octobre 2000 etjuin 2001, les experts ont présenté, selon leur champ de compétence, uneanalyse critique et une synthèse des travaux publiés sur les différents aspects duthème traité. Les trois dernières séances ont été consacrées à l’élaboration desprincipales conclusions et des recommandations.
Published: 2001

21. The time devoted to sport activities is associated with different risk of exercise addiction and alcohol use disorder

Author: Vansteene, Clément, Kaya Lefèvre, Héline, Gorwood, Philip, GHU Paris Psychiatrie et Neurosciences, Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Université de Paris (UP), Laboratoire de Psychopathologie et Processus de Santé (LPPS (URP_4057)), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Martinez Rico, Clara, Hôpital Sainte-Anne-Université Paris Cité (UPCité), Université Paris Cité (UPCité), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
Subjects: [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, alcohol, physical activity, addiction, exercise addiction, sport, human activities, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Although sport activities have beneficial effects on health, excessive practice can lead to exercise addiction (EA). Previous studies have shown comorbidity between EA and alcohol use disorder, but how we could conciliate this observation with the positive effects of sport requests further research. This study aims to investigate the relationship between a proxy of alcohol use disorder and sport practice, more specifically focusing on EA, in a representative sample of the French population. Two thousand and two participants were recruited online and selected to represent the French adult population. Participants were asked to answer questions regarding sport activity, with the EAI questionnaire investigating exercise addiction, and alcohol consumption, with the CAGE questionnaire investigating a proxy of alcohol use disorder (score≥2). Alcohol use and alcohol use disorder were associated with a higher risk of exercise addiction and with more time devoted to collective sports (such as football) and two-person sports (such as tennis). The risk of alcohol use disorder seems to increase with the level of physical activity for collective sport, but to decrease for individual sports (such as running). Results support the hypothesis that the time devoted to different types of sport have different risks for exercise addiction (individual sports being more clearly concerned) and alcohol use disorder (especially for collective sports). Furthermore, the observed association between sport addiction and alcohol use disorder showes that the detrimental effect of sport on the risk of alcohol use disorder could be mediated by high level of sport activities. The social dimension of collective sports should be further investigated to facilitate preventive approaches.
Published: 2021
Full Text: View/download PDF

22. Self-harm hospitalization following bariatric surgery in adolescents and young adults

Author: K. Goueslard, F. Jollant, J.M. Petit, C. Quantin, Service Biostatistiques et Informatique Médicale (CHU de Dijon) (DIM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Jena University Hospital [Jena], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), GHU Paris Psychiatrie et Neurosciences, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), McGill University = Université McGill [Montréal, Canada], Université Paris Cité - UFR Médecine [Santé] (UPCité UFR Médecine), Université Paris Cité (UPCité), CHU Dijon, Université Bourgogne Franche-Comté [COMUE] (UBFC), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 2018 grant on 'suicidal behavior in youths' from the Department for Research, Studies, Evaluation and Statistics (DREES), French Health and Social Affairs Ministry, Paris, France., and HAL UVSQ, Équipe
Subjects: Adult, Male, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, Adolescent, Bariatric Surgery, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, Critical Care and Intensive Care Medicine, Adolescents, Health data, Young Adult, Postoperative Complications, Risk Factors, Self-harm, Humans, Obesity, Postoperative Period, Child, Nutrition and Dietetics, Mental Disorders, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Hospitalization, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Case-Control Studies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, France, Self-Injurious Behavior, Young adults
Abstract: International audience; Background: While bariatric surgery has demonstrated physical and psychological benefits, a risk of suicide and non-fatal self-harm has also been shown. The aim of this study was to compared the rate of hospitalization for self-harm during a three-year observational follow-up period between adolescents/young adults who underwent bariatric surgery in France in 2013–2014 and two control groups. Methods: All individuals aged 12–25 years old who underwent bariatric surgery in France between January 1st, 2013, and December 31st, 2014, were identified with a validated algorithm from the French national hospital database, and compared to a healthy sample of the general population matched for age and gender. Information relative to hospitalizations, including for self-harm (ICD-10 codes X60-84), were extracted i) between 2008 and the surgery, and ii) for a three-year follow-up period. A second unmatched control group with obesity but no bariatric surgery was also identified. Survival analyses with adjustments for confounding variables were used. Results: In 2013–2014, 1984 youths had bariatric surgery in France. During follow-up, 1.5% were hospitalized for self-harm vs. 0.3% for controls (p < 0.0001). After adjustment, subsequent hospitalization for self-harm was associated with bariatric surgery (HR 3.64, 95% CI 1.70–7.81), prior psychiatric disorders (HR 7.76, 95% CI 3.76–16.01), and prior self-harm (HR 4.43, 95% CI 1.75–11.24). When compared to non-operated youths with obesity, bariatric surgery was not associated with self-harm while prior mental disorders and self-harm were. Mortality reached 0.3% after surgery. Conclusions: Bariatric surgery is associated with an increased risk of self-harm, mainly in relation to preexisting psychological conditions. Vigilance and appropriate care are thus warranted in vulnerable individuals.
Published: 2021
Full Text: View/download PDF

23. Non-invasive and invasive brain stimulation in alcohol use disorders: A critical review of selected human evidence and methodological considerations to guide future research

Author: K. Bihan, L. Silveira-Reis-Brito, Antoni Valero-Cabré, Redwan Maatoug, Philibert Duriez, Bruno Millet, A. Benyamina, P. Podevin, Service de psychiatrie adulte [CHU Pitié-Salpêtière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de pharmacologie médicale [CHU Pitié-Salpêtrière], Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Paul Brousse, Boston University [Boston] (BU), Open University of Catalonia [Barcelona], Universitat Oberta de Catalunya (UOC), Service de Psychiatrie Adulte [CHU Pitié-Salpêtière], Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Pharmacologie médicale [CHU Pitié-Salpêtrière], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Sainte-Anne-Université Paris Cité (UPCité), and Gestionnaire, Hal Sorbonne Université
Subjects: medicine.medical_treatment, [SDV]Life Sciences [q-bio], RC435-571, Craving, Alcohol use disorder, Transcranial Direct Current Stimulation, Brain stimulation techniques, 0302 clinical medicine, Deep brain stimulation, 030212 general & internal medicine, Psychiatry, Transcranial direct-current stimulation, Neuromodulation, Rehabilitation, Brain, Transcranial Magnetic Stimulation, Neuromodulation (medicine), psychiatry, 3. Good health, deep brain stimulation, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Clinical Psychology, Alcoholism, substance use disorders, neuromodulation, Addictology, medicine.symptom, medicine.medical_specialty, Repetitive transcranial magnetic stimulation, alcohol use disorder, brain stimulation techniques, rehabilitation, 03 medical and health sciences, Physical medicine and rehabilitation, mental disorders, medicine, Humans, Neurostimulation, Substance use disorders, business.industry, transcranial direct-current stimulation, repetitive transcranial magnetic stimulation, medicine.disease, addictology, Transcranial magnetic stimulation, Brain stimulation, Quality of Life, business, 030217 neurology & neurosurgery
Abstract: International audience; Introduction: Alcohol use disorder (AUD) ranks among the leading causes of decrements in disability-adjusted life-years. Long-term exposure to alcohol leads to an imbalance of activity between frontal cortical systems and the striatum, thereby enhancing impulsive behaviours and weakening inhibitory control. Alternative therapeutic approaches such as non-invasive and invasive brain stimulation have gained some momentum in the field of addictology by capitalizing on their ability to target specific anatomical structures and correct abnormalities in dysfunctional brain circuits.Materials and methods: The current review, covers original peer-reviewed published research on the use of brain stimulation methods for the rehabilitation of AUD. A broad and systematic search was carried out on four electronic databases: NCBI PubMed, Web of Science, Handbooks and the Cochrane Library. Any original article in English or French language, without restrictions of patient age or gender, article type and publication outlet, were included in the final pool of selected studies.Results: The outcomes of this systematic review suggest that the dorsolateral prefrontral cortex (DLPFC) is a promising target for treating AUD with high frequency repetitive transcranial magnetic stimulation. Such effect would reduce feelings of craving by enhancing cognitive control and modulating striatal function. Existing literature also supports the notion that changes of DLPFC activity driven by transcranial direct current stimulation, could decrease alcohol craving and consumption. However, to date, no major differences have been found between the efficacy of these two non-invasive brain-stimulation approaches, which require further confirmation. In contrast, beneficial stronger evidence supports an impact of deep brain stimulation reducing craving and improving quality of life in AUD, effects that would be mediated by an impact on the nucleus accumbens, a central structure of the brain's reward circuitry. Overall, neurostimulation shows promise contributing to the treatment of AUD. Nonetheless, progress has been limited by a number of factors such as the low number of controlled randomized trials, small sample sizes, variety of stimulation parameters precluding comparability and incomplete or questionable sham-conditions. Additionally, a lack of data concerning clinical impact on the severity of AUD or craving and the short follow up periods precluding and accurate estimation of effect duration after discontinuing the treatment, has also limited the clinical relevance of final outcomes.Conclusion: Brain stimulation remains a promising approach to contribute to AUD therapy, co-adjuvant of more conventional procedures. However, a stronger therapeutic rational based on solid physio-pathological evidence and accurate estimates of efficacy, are still required to achieve further therapeutic success and expand clinical use.
Published: 2021
Full Text: View/download PDF

24. Familial experience of acute bacterial meningitis in children: a transversal qualitative study using interpretative phenomenological analysis

Author: Léonor Fasse, Philip Gorwood, Elisabetta Scanferla, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), GHU Paris Psychiatrie et Neurosciences, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Laboratoire de Psychopathologie et Processus de Santé (LPPS (URP_4057)), Université de Paris (UP), Département Interdisciplinaire de Soins de Support aux Patients en Onco-hématologie [Gustave Roussy] (DISSPO), Institut Gustave Roussy (IGR), Hôpital Sainte-Anne-Université Paris Cité (UPCité), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université Paris Cité (UPCité), and Martinez Rico, Clara
Subjects: intensive & critical care, Adult, Adolescent, [SDV]Life Sciences [q-bio], Disease, Superordinate goals, Meningitis, Bacterial, 03 medical and health sciences, Young Adult, 0302 clinical medicine, 030225 pediatrics, Health care, Adaptation, Psychological, medicine, Humans, Family, 030212 general & internal medicine, Survivors, Sibling, Child, Qualitative Research, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Interpretative phenomenological analysis, business.industry, Infant, infectious disease/HIV, General Medicine, medicine.disease, psychiatry, [SDV] Life Sciences [q-bio], Neurology, Child, Preschool, Medicine, Female, business, Meningitis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Qualitative research, Clinical psychology, Meaning (linguistics)
Abstract: ObjectivesTo capture the subjective experience of close family ascendants of acute bacterial meningitis survivors and to explore how they give meaning to this specific experience.DesignA qualitative study of indepth interviews using interpretative phenomenological analysis.Primary outcomeMain meaning-making processes of participants’ experience.SettingsParticipants were recruited through two associations of people affected by meningitis and their family ascendants.ParticipantsConvenience sampling of 11 women whose children or grandchildren were between 0.2 and 20 years old at the time of their meningitis diagnosis (M=4.06, SD=7.3). On average, 9.39 (SD=5.4) years had passed between the onset of illness and the interview.ResultsSix superordinate themes (meningitis disease; healthcare services and professionals; knowledge/ignorance; repercussions of the meningitis experience: ‘life afterwards’; sick child attitudes/behaviour; and sibling attitudes/behaviour) and two main meaning-making processes in relation to participants’ experience of meningitis were identified: (1) the sick child becoming a ‘hero’: comparison with other children; and (2) engaging action/attitude: finding the ‘positive’ of the traumatic experience and engaging action to improve the care system. These two processes underpin the psychological adjustment to meningitis and its consequences.ConclusionsThis study provides a unique insight into close family members’ first-hand experience with acute bacterial meningitis. Findings highlighted factors characterising the disease experience, the psychological adjustment of meningitis survivors’ families and their meaning-making processes. These findings are important for research and clinical practice, demonstrating the multidimensional impact of the disease on family ascendants, their need for professional psychological support and the importance of direct involvement of parents in identifying key aspects of care.
Published: 2021
Full Text: View/download PDF

25. Increased cognitive flexibility mediates the improvement of eating disorders symptoms, depressive symptoms and level of daily life functioning in patients with anorexia nervosa treated in specialised centres

Author: Laura Di Lodovico, Odile Viltart, Philibert Duriez, Héline Kaya Lefèvre, Philip Gorwood, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), GHU Paris Psychiatrie et Neurosciences, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Laboratoire de Psychopathologie et Processus de Santé (LPPS - EA 4057), Université de Paris (UP), Cité scientifique / SN4 [Villeneuve d'Ascq] (Université de Lille), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Sainte-Anne-Université Paris Cité (UPCité), Laboratoire de Psychopathologie et Processus de Santé (LPPS (URP_4057)), Université Paris Cité (UPCité), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Sainte Anne [Paris], Université de Lille - UFR des Humanités (Lille UFRH), Université de Lille, CNRS, CHU Lille, Institut de psychiatrie et neurosciences de Paris [IPNP - U1266 Inserm], Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 [SCALab], and Dupuis, Christine
Subjects: 050103 clinical psychology, [SHS.PSY]Humanities and Social Sciences/Psychology, eating disorders, Anxiety, Anorexia nervosa, Anorexia Nervosa, Cognition, Depression, Feeding and Eating Disorders, Female, Humans, anorexia nervosa, cognitive flexibility, depressive symptoms, treatment efficacy, 03 medical and health sciences, 0302 clinical medicine, Neuroimaging, medicine, 0501 psychology and cognitive sciences, ComputingMilieux_MISCELLANEOUS, Depression (differential diagnoses), 2. Zero hunger, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, 05 social sciences, Cognitive flexibility, medicine.disease, 3. Good health, 030227 psychiatry, Psychiatry and Mental health, Clinical Psychology, Eating disorders, medicine.symptom, business, Body mass index, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Clinical psychology
Abstract: International audience; Objective: Poor cognitive flexibility has been highlighted in patients with anorexia nervosa (AN), contributing to the development and maintenance of symptoms. The aim of the present study is to investigate how enhanced cognitive flexibility is involved in treatment outcomes in patients with AN.Method: One hundred thirty female out-patients treated for AN have been assessed at baseline and after 4 months of treatment. Path analyses were used to investigate the mediating role of cognitive flexibility, measured through the Brixton test, on a wide range of outcomes: body mass index, eating disorder symptoms, daily life functioning, anxiety, depression, emotions, self-rated silhouette.Results: Cognitive flexibility was improved during treatment, and enhanced cognitive flexibility explains a significant part of level of the improvement in daily life functioning (26%), reduction of eating disorder symptoms (18%) and reduction of depressive symptoms (17%). Others outcomes were also improved, but these improvements were not mediated by cognitive flexibility.Conclusions: Results suggest that enhancing cognitive flexibility could help reduce rigid cognitive and behavioural patterns involved in AN, thus improving everyday functioning and clinical severity. Further studies combining different types of cognitive flexibility evaluation as well as neuroimaging may be necessary to better establish which of its aspects are involved in patients' improvement.
Published: 2021
Full Text: View/download PDF

26. The Early Impact of the COVID-19 Lockdown on Stress and Addictive Behaviors in an Alcohol-Consuming Student Population in France

Author: Valentin Flaudias, Oulmann Zerhouni, Bruno Pereira, Cheryl J. Cherpitel, Jordane Boudesseul, Ingrid de Chazeron, Lucia Romo, Sébastien Guillaume, Ludovic Samalin, Julien Cabe, Laurent Bègue, Laurent Gerbaud, Benjamin Rolland, Pierre-Michel Llorca, Mickael Naassila, Georges Brousse, CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire Parisien de Psychologie Sociale (LAPPS), Université Paris 8 Vincennes-Saint-Denis (UP8)-Université Paris Nanterre (UPN), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire Inter-universitaire de Psychologie : Personnalité, Cognition, Changement Social (LIP-PC2S), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Université Grenoble Alpes (UGA), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), RIQUOIR, GAELLE, CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Université Paris Nanterre (UPN)-Université Paris 8 Vincennes-Saint-Denis (UP8), Hôpital Sainte-Anne-Université de Paris (UP), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Boudesseul, Jordane
Subjects: medicine.medical_specialty, lcsh:RC435-571, LockDown, media_common.quotation_subject, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, purl.org/pe-repo/ocde/ford#5.01.00 [https], Protective factor, 030508 substance abuse, Alcohol, Stress, 03 medical and health sciences, chemistry.chemical_compound, Social support, 0302 clinical medicine, lcsh:Psychiatry, Stress (linguistics), Medicine, 030212 general & internal medicine, College students, Estrés, media_common, Original Research, Psychiatry, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, alcohol, Public health, Addiction, Psicología / Psicología social, Stressor, public health, COVID-19, Estudiantes universitarios, Coronavirus, Psychiatry and Mental health, chemistry, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, stressors, addiction, Worry, 0305 other medical science, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Clinical psychology
Abstract: Indexado en Scopus This study evaluated factors linked with perceived stress related to the COVID-19 pandemic and lockdown and addictive behaviors prior to and during lockdown in a sample of students who indicated engaging in alcohol consumption behaviors before lockdown. Methods: Cross-sectional study. French students from four universities participated in this study, and 2,760 students reported alcohol use. During the first week of lockdown, students reported their perceived levels of stress regarding COVID-19. Substance use and addictive behaviors were reported before and during lockdown, and media exposure, demographical, living conditions, and environmental stressors were reported during lockdown. Results: Women reported greater levels of stress (95% CI: 1.18 to 1.93, p < 0.001). Highly-stressed students also report less social support (95% CI: -1.04 to -0.39, p < 0.001) and were more likely to worry about the lockdown (95% CI: 0.27 to -0.65, p < 0.001). Alcohol-related problemswere more prevalent among the most stressed students (95% CI: 0.02 to 0.09, p = 0.004) as well as eating problems (95% CI: 0.04 to 0.36, p = 0.016) and problematic internet use (95% CI, 0.06 to 0.14, p < 0.001). Students reporting the highest levels of stress also indicated more compulsive eating during the previous seven days (95% CI, 0.21 to 1.19, p = 0.005). Conclusions: The level of stress was strongly related to four categories of variables: (i) intrinsic characteristics, (ii) addictive behaviors before lockdown, (iii) lockdown-specific conditions, and (iv) addictive behaviors during the lockdown. Several variables linked to COVID-19 were not directly linked with perceived stress, while perceived stress was found to correlate with daily life organization-related uncertainty and anticipated consequences of lockdown. Importantly, social support seems to be a protective factor on high level of stress. Este estudio evaluó los factores relacionados con el estrés percibido relacionado con la pandemia de COVID-19 y el encierro y las conductas adictivas antes y durante el encierro en una muestra de estudiantes que indicaron participar en comportamientos de consumo de alcohol antes del encierro. Métodos: estudio transversal. En este estudio participaron estudiantes franceses de cuatro universidades y 2.760 estudiantes informaron haber consumido alcohol. Durante la primera semana de encierro, los estudiantes informaron sobre sus niveles percibidos de estrés con respecto a COVID-19. Se informó el uso de sustancias y los comportamientos adictivos antes y durante el encierro, y se informó sobre la exposición a los medios, las condiciones demográficas, de vida y los factores estresantes ambientales durante el encierro. Resultados: las mujeres informaron mayores niveles de estrés (IC del 95%: 1,18 a 1,93, p
Published: 2021
Full Text: View/download PDF

27. One year after the COVID-19: What have we learnt, what shall we do next?

Author: Philip Gorwood, Andrea Fiorillo, Gorwood, Philip, Fiorillo, Andrea, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), GHU Paris Psychiatrie et Neurosciences, University of the Study of Campania Luigi Vanvitelli, Martinez Rico, Clara, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and Hôpital Sainte-Anne-Université Paris Cité (UPCité)
Subjects: 2019-20 coronavirus outbreak, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, 030227 psychiatry, World Wide Web, 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, Viewpoint, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Psychology, 030217 neurology & neurosurgery, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; No abstract available
Published: 2021
Full Text: View/download PDF

28. Risky decision-making in suicide attempters, and the choice of a violent suicidal means: an updated meta-analysis

Author: Roland Dardennes, Fabrice Jollant, Rebecca Perrain, GHU Paris Psychiatrie et Neurosciences, Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Santé mentale et santé publique (SMSP - U1178), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), McGill University = Université McGill [Montréal, Canada], CCSD, Accord Elsevier, and Hôpital Sainte-Anne-Université Paris Cité (UPCité)
Subjects: [SDV]Life Sciences [q-bio], vulnerability, neuropsychology, violent suicide, Suicide, Attempted, suicidal behavior, Neuropsychological Tests, decision making, Suicidal Ideation, 03 medical and health sciences, 0302 clinical medicine, Group differences, medicine, Humans, risk, Suicide attempters, Significant difference, Neuropsychology, 16. Peace & justice, medicine.disease, Iowa gambling task, 030227 psychiatry, 3. Good health, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Clinical Psychology, Mood, Mood disorders, Meta-analysis, Gambling, Psychology, 030217 neurology & neurosurgery, Clinical psychology
Abstract: Background Studies showed disadvantageous decision-making in suicide attempters. The present meta-analysis aims to examine the stability of these findings and related questions. Methods EMBASE and Pubmed databases were searched for studies published between 01/01/2000 and 01/01/2020 with an additional search through bibliographical references. English or French articles published in peer-reviewed journals, reporting quantitative task-based measures of decision-making in suicide attempters were included: 3,582 records were identified, 33 full-text articles screened, and 21 articles finally included. Results All studies were conducted in mood disorders; 18 used the Iowa Gambling Task (IGT) and 3 the Cambridge Gamble Task (CGT). With the IGT, suicide attempters showed riskier choices than patient controls (Hedges’ g=-0.28 95%CI (-0.44 – -0.12)) and healthy controls (g=-0.54 (-0.83 – -0.25)) with no significant difference between control groups. The difference between suicide attempters and patient controls was not related to age group, mood disorder type, author, or research center while an effect of time of publication was found (p=0.006). Poorer performance was also found in suicide attempters compared to patient controls when using the CGT (g=-0.57 95%CI (-0.82 – -0.31)). Suicide attempters who used a violent means showed poorer IGT performance than those who used a non-violent means (3 studies). Limitation Limited number of studies outside mood disorders. No data to calculate a gender effect. Conclusion The present meta-analysis confirmed riskier decision-making in suicide attempters. Although group differences appear to be of modest effect size in general, they were particularly marked in the subgroup of those who used a violent suicidal means.
Published: 2021
Full Text: View/download PDF

29. Evaluation of muscle-skeletal strength and peak expiratory flow in severely malnourished inpatients with anorexia nervosa: A pilot study

Author: Haykanush Ohanyan, Laura Di Lodovico, Marika Dicembre, Emilio Minano Garrido, Jean-Claude Melchior, M. Duquesnoy, Mouna Hanachi, Hôpital Paul Brousse, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), and AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Subjects: 0301 basic medicine, Male, Endocrinology, Diabetes and Metabolism, [SDV]Life Sciences [q-bio], 030209 endocrinology & metabolism, Pilot Projects, Body Mass Index, Manual Muscle Testing, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, 2. Zero hunger, Inpatients, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, Muscle strength, Muscles, Malnutrition, Muscle weakness, Anorexia nervosa, medicine.disease, PEF, 3. Good health, MMT, Parenteral nutrition, Anorexia nervosa (differential diagnoses), Anesthesia, Transaminitis, Female, medicine.symptom, business, Body mass index
Abstract: International audience; Objectives: Anorexia nervosa is a complex psychiatric disorder that can lead to specific somatic complications. Malnutrition is frequent and can involve a decrease of mobility, up to functional impotence, in individuals with extremely severe cases. The aim of this pilot study was to examine muscle strength and peak expiratory flow (PEF) in severely undernourished patients with anorexia nervosa at admission and after 5 wk of renutrition by tube feeding, and to find the clinical and biological correlates of muscle-strength impairment. Methods: A prospective observational study was conducted over 6 mo. Manual muscle testing, measures of PEF, and clinical and biologic assessments were performed at baseline and after 5 wk of renutrition. Results: Twenty-three extremely malnourished female participants (mean body mass index: 11.4 ± 1.3 kg/m2) were included. All participants had global impairment in muscle strength (manual muscle testing: 37.7 ± 7.7) and PEF (253.3 ± 60 mL/min) at admission. Muscle weakness was higher in axial than peripheral muscle groups (P < 0.01), with no significant difference between proximal and distal muscles (P > 0.05). Muscle strength at admission was significantly associated with severity of undernourishment (body mass index and albumin) and transaminitis (P < 0.05). At follow-up, musculoskeletal strength and PEF were significantly improved after partial weight recovery (P < 0.01). Conclusions: Extremely undernourished people with anorexia nervosa present a decrease of PEF and musculoskeletal strength predominant on axial muscles. Both are associated with severity of malnutrition and liver damage. Partial recovery was observed after 5 wk of enteral nutrition.
Published: 2021
Full Text: View/download PDF

30. Mental health services during the first wave of the COVID-19 pandemic in Europe: Results from the EPA Ambassadors Survey and implications for clinical practice

Author: Simavi Vahip, Anne Kleinberg, Martina Rojnic Kuzman, Mariana Pinto da Costa, Celso Arango, Lubomira Izakova, Jana Chihai, Ramune Mazaliauskiene, Geert Dom, Andrea Fiorillo, Goran Mihajlović, Pavel Mohr, Julian Beezhold, William Flannery, Doina Cozman, Judit Balazs, Jerzy Samochowiec, Izet Pajević, Oleg Skugarevsky, Eka Chkonia, Philip Goorwod, Alma Mihaljević Peleš, University Hospital Centre Zagreb, Partenaires INRAE, Ege university, University of the Study of Campania Luigi Vanvitelli, University of East Anglia [Norwich] (UEA), King‘s College London, Institute of Biomedical Sciences Abel Salazar - ICBAS [Porto, Portugal], Belarusian State Medical University (BSMU), The Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp (UA), Univerzitet u Tuzli [Tuzla, Bosnie-Herzégovine], Charles University [Prague] (CU), Tallinn Children's Hospital [Tallinn, Estonia], University of Tartu, Tbilisi State University, Eötvös Loránd University (ELTE), Bjørknes University College [Oslo, Norvège], Mater Misericordiae University Hospital [Dublin] (The Mater Hospital), Hospital of Lithuanian University of Health Sciences Kauno Klinikos [Kaunas, Lithuania], University Nicolae Testemitanu [Kishinev, Moldova] (UNT), West Pomeranian University of Technology Szczecin, Iuliu Hatieganu University of Medicine & Pharmacy, University of Kragujevac, Comenius University in Bratislava, Spanish Society of Psychiatry [Madrid, Spain] (SSP), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Mater Misericordiae University Hospital (The Mater Hospital), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Sainte-Anne-Université Paris Cité (UPCité), and Martinez Rico, Clara
Subjects: Adult, Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Service delivery framework, Care, mental health, policy, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, Pandemic, Health care, medicine, Humans, Psychology, Pandemics, Societies, Medical, ComputingMilieux_MISCELLANEOUS, Psychiatry, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Mental Disorders, Telepsychiatry, COVID-19, mental health services, Middle Aged, EPA Policy Paper, Mental health, 3. Good health, 030227 psychiatry, Clinical Practice, Europe, Psychiatry and Mental health, Family medicine, Professional association, Female, Human medicine, business, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background The COVID-19 pandemic caused an unprecedented worldwide crisis affecting several sectors, including health, social care, economy and society at large. The World Health Organisation has emphasized that mental health care should be considered as one of the core sectors within the overall COVID-19 health response. By March 2020, recommendations for the organization of mental health services across Europe have been developed by several national and international mental health professional associations. Methods The European Psychiatric Association (EPA) surveyed a large European sample of psychiatrists, namely the EPA Ambassadors, on their clinical experience of the impact of COVID-19 pandemic on the treatment of psychiatric patients during the month of April 2020 in order to: a) identify and report the views and experiences of European psychiatrists; and b) represent and share these results with mental health policy makers at European level. Based on the recommendations issued by national psychiatric associations and on the results of our survey, we identified important organisational aspects of mental health care during the peak of the first wave of the COVID-19. Results While most of the recommendations followed the same principles, significant differences between countries emerged in service delivery, mainly relating to referrals to outpatients and for inpatient admission, assessments and treatment for people with mental disorders. Compared to previous months, the mean number of patients treated by psychiatrists in outpatient settings halved in April 2020. In the same period, the number of mentally ill patients tested for, or developing, COVID-19 was low. In most of countries, traditional face-to-face visits were replaced by online remote consultations. Conclusions Based on our findings we recommend: 1) to implement professional guidelines into practice and harmonize psychiatric clinical practice across Europe; 2) to monitor the treatment outcomes of patients with COVID-19 and pre-existing mental disorders; 3) to keep psychiatric services active by using all available options (for example telepsychiatry); 4) to increase communication and cooperation between different health care providers., European Psychiatric Association, The work was funded by the European Psychiatric Association.
Published: 2021
Full Text: View/download PDF

31. Corticotropin releasing hormone receptor CRHR1 gene is associated with tianeptine antidepressant response in a large sample of outpatients from real-life settings

Author: Nicolas Ramoz, Nicolas Hoertel, Bénédicte Nobile, Géraldine Voegeli, Ariane Nasr, Yann Le Strat, Philippe Courtet, Philip Gorwood, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de psychiatrie [Corentin Celon], Hôpital Corentin Celton [Issy-les-Moulineaux], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), Service de psychiatry [Louis Mourier], Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Martinez Rico, Clara, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Sainte-Anne-Université de Paris (UP), and Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, Depressive Disorder, Major, Hypothalamo-Hypophyseal System, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Corticotropin-Releasing Hormone, Thiazepines, [SDV]Life Sciences [q-bio], Pituitary-Adrenal System, LIM Domain Proteins, Receptors, Corticotropin-Releasing Hormone, Antidepressive Agents, Article, lcsh:RC321-571, [SDV] Life Sciences [q-bio], Prognostic markers, Outpatients, Humans, Female, Clinical genetics, Carrier Proteins, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Polymorphisms of genes involved in the hypothalamic-pituitary-adrenocortical (HPA) axis have been associated with response to several antidepressant treatments in patients suffering of depression. These pharmacogenetics findings have been reported from independent cohorts of patients mostly treated with selective serotonin reuptake inhibitors, tricyclic antidepressant, and mirtazapine. Tianeptine, an atypical antidepressant, recently identified as a mu opioid receptor agonist, which prevents and reverses the stress induced by glucocorticoids, has been investigated in this present pharmacogenetics study. More than 3200 Caucasian outpatients with a major depressive episode (MDE) from real-life settings were herein analyzed for clinical response to tianeptine, a treatment initiated from 79.5% of the subjects, during 6-8 weeks follow-up, assessing polymorphisms targeting four genes involved in the HPA axis (NR3C1, FKPB5, CRHR1, and AVPR1B). We found a significant association (p < 0.001) between CRHR1 gene variants rs878886 and rs16940665, or haplotype rs878886*C-rs16940665*T, and tianeptine antidepressant response and remission according to the hospital anxiety and depression scale. Analyses, including a structural equation model with simple mediation, suggest a moderate effect of sociodemographic characteristics and depressive disorder features on treatment response in individuals carrying the antidepressant responder allele rs8788861 (allele C). These findings suggest direct pharmacological consequences of CRHR1 polymorphisms in the antidepressant tianeptine response and remission, in MDE patients. This study replicates the association of the CRHR1 gene, involved in the HPA axis, with (1) a specificity attributed to treatment response, (2) a lower risk of chance finding, and in (3) an ecological situation.
Published: 2020
Full Text: View/download PDF

32. Sustained Recovery in a Treatment-Refractory Obsessive–Compulsive Disorder Patient After Deep Brain Stimulation Battery Failure

Author: Redwan Maatoug, Antoni Valero-Cabré, Philibert Duriez, Bertrand Saudreau, Sara Fernández-Vidal, Carine Karachi, Bruno Millet, Service de psychiatrie adulte [CHU Pitié-Salpêtière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Boston University School of Medicine (BUSM), Boston University [Boston] (BU), Open University of Catalonia [Barcelona], Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Centre de Neuro-Imagerie de Recherche (CENIR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Service de Neurochirurgie [CHU Pitié-Salpêtrière]
Subjects: Deep brain stimulation, lcsh:RC435-571, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Case Report, Placebo, Asymptomatic, behavioral disciplines and activities, 03 medical and health sciences, treatment refractory, 0302 clinical medicine, lcsh:Psychiatry, obsessive compulsive disorder, medicine, case-report, Psychiatry, stimulation techniques, Treatment refractory, business.industry, Ventral striatum, 3. Good health, 030227 psychiatry, deep brain stimulation, Psychiatry and Mental health, Distress, battery failure, medicine.anatomical_structure, Anesthesia, Brain stimulation, Anxiety, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract: International audience; Obsessive-compulsive disorder (OCD) is a widespread chronic neuropsychiatric disorder characterized by recurrent intrusive thoughts, images, or urges (obsessions) that typically cause anxiety or distress. Even when optimal treatment is provided, 10% of patients remain severely affected chronically. In some countries, deep brain stimulation (DBS) is an approved and effective therapy for patients suffering from treatment-resistant OCD. Hereafter, we report the case of a middle-aged man with a long history of treatment-resistant OCD spanning nearly a decade with Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores oscillating between 21 and 28. The patient underwent bilateral implantation of ventral striatum/ventral capsule DBS leads attached to a battery-operated implanted pulse generator. After a 3-month postimplantation period, the DBS protocol started. Three months after the onset of DBS treatment, the patient's Y-BOCS score had dropped to 3, and he became steadily asymptomatic. However, inadvertently, at this time, it was found out that the implanted pulse generator battery had discharged completely, interrupting brain stimulation. The medical team carried on with the original therapeutic and evaluation plan in the absence of active DBS current. After 12 additional months under off-DBS, the patient remained at a Y-BOCS score of 7 and asymptomatic. To our knowledge, this is the first report that provides an opportunity to discuss four different hypotheses of long-term recovery induced by DBS in a treatment-refractory OCD patient, notably: (1) A placebo effect; (2) Paradoxical improvements induced by micro-lesions generated by DBS probe implantation procedures; (3) Unexpected late spontaneous improvements; (4) Recovery driven by a combination of active DBS-induction, the effects of medication, and DBS-placebo effects.
Published: 2020
Full Text: View/download PDF

33. Identification of rare variants in CADM1 in patients with anorexia nervosa

Author: Nicolas Lebrun, Nicolas Ramoz, Thierry Bienvenu, Philip Gorwood, Julia Clarke, Zhengyu Lin, Philibert Duriez, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), and Centre Hospitalier Sainte Anne [Paris]
Subjects: Adult, Male, Linkage disequilibrium, Anorexia Nervosa, [SDV]Life Sciences [q-bio], Single-nucleotide polymorphism, Genome-wide association study, Biology, Polymorphism, Single Nucleotide, Linkage Disequilibrium, Cohort Studies, Young Adult, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Humans, Missense mutation, Coding region, SNP, Genetic Predisposition to Disease, Gene, Biological Psychiatry, Sanger sequencing, Genetics, Cell Adhesion Molecule-1, Genetic Variation, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, symbols, Female, 030217 neurology & neurosurgery, Genome-Wide Association Study
Abstract: As a polygenic psychiatric disorder, the genetics of anorexia nervosa (AN) remains largely unexplored. Recently a large GWAS meta-analysis identified a significant SNP (rs6589488) as associated with AN. We suggested that rs6589488 might have gotten its association as being in linkage disequilibrium with unknown variants or functional intronic variants. In a selective cohort containing 51 patients diagnosed with restrictive subtype AN, we screened the whole coding region of the CADM1gene by Sanger sequencing and further investigated if these variants are associated with specific outcome. Only 13 single nucleotide polymorphisms, including 2 missense variants, 2 synonymous variants, 2 variants located at 5′-UTR and 7 intronic variants, including rs6589488, were identified in our AN cohort. The 2 missense variants, p.Val5Leu and p.Asp285Glu were not predicted to be deleterious. In conclusion, the intronic initial variant appears to be not associated with causative coding variant in the vicinity. If CADM1 is not the AN predisposition factor, the causative variant probably lies within 1 Mb of CADM1. Interestingly, among the 7 closest genes to CADM1, the nicotinamide N-methyltransferase (NNMT) gene is known to be associated with obesity. We suggest that the intronic variant in CADM1 could be in linkage disequilibrium with other causative variants located in NNMT.
Published: 2020
Full Text: View/download PDF

34. How mental health care should change as a consequence of the COVID-19 pandemic

Author: Jimmy Chee Keong Lee, Eric Y.H. Chen, Mary Cannon, Carlos López-Jaramillo, Christoph U. Correll, Jeffrey A. Lieberman, Louise Byrne, Nev Jones, Hiroyuki Uchida, Sarah Carr, Merete Nordentoft, Celso Arango, Michael Phillips, Nicholas Crossley, Antonio Vita, Silvana Galderisi, Miia Männikkö, Til Wykes, Eduard Vieta, Sonia Johnson, Philip Gorwood, Hilkka Kärkkäinen, Carmen Moreno, John H. Krystal, Hospital General Universitario 'Gregorio Marañón' [Madrid], Centro de Investigación Biomédica en Red Salud Mental [Madrid] (CIBER-SAM), King‘s College London, South London and Maudsley NHS Foundation Trust, University of Campania 'Luigi Vanvitelli', University of Copenhagen = Københavns Universitet (UCPH), Pontificia Universidad Católica de Chile (UC), University of South Florida [Tampa] (USF), Royal College of Surgeons in Ireland (RCSI), The Zucker Hillside Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University [Hempstead], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Royal Melbourne Institute of Technology University (RMIT University), University of Birmingham [Birmingham], The University of Hong Kong (HKU), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), University College of London [London] (UCL), Global Alliance of Mental Illness Advocacy Networks-Europe [Brussels], Yale New Haven Hospital, Institute of Mental Health [Singapore], Nanyang Technological University [Singapour], Columbia University [New York], Universidad de Antioquia = University of Antioquia [Medellín, Colombia], EUFAMI [Leuven], Shanghai Jiao Tong University School of Medicine, Keio University School of Medicine [Tokyo, Japan], University of Barcelona, University of Brescia, Spedali Civili Hospital [Brescia], Martinez Rico, Clara, Lee Kong Chian School of Medicine (LKCMedicine), Moreno, C., Wykes, T., Galderisi, S., Nordentoft, M., Crossley, N., Jones, N., Cannon, M., Correll, C. U., Byrne, L., Carr, S., Chen, E. Y. H., Gorwood, P., Johnson, S., Karkkainen, H., Krystal, J. H., Lee, J., Lieberman, J., Lopez-Jaramillo, C., Mannikko, M., Phillips, M. R., Uchida, H., Vieta, E., Vita, A., Arango, C., University of Copenhagen = Københavns Universitet (KU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), and Hôpital Sainte-Anne-Université de Paris (UP)
Subjects: COVID-19 Pandemic, Corrections, Continuous assessment, Betacoronavirus, Coronavirus Infections, Health Personnel, Humans, Mental Disorders, Mental Health Services, Pandemics, Pneumonia, Viral, Telemedicine, 0302 clinical medicine, Pandemic, Infection control, Cameroon, 030212 general & internal medicine, Viral, Psychiatry, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, 1. No poverty, 3. Good health, Psychiatry and Mental health, Mental Health, General [Science], Mental health care, Psychology, 2019-20 coronavirus outbreak, Mental Health Care, Coronavirus disease 2019 (COVID-19), Distancing, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, Salud mental, Article, Interconnectedness, 03 medical and health sciences, Nursing, Environmental health, Correspondence, Biological Psychiatry, SARS-CoV-2, COVID-19, Pneumonia, Mental health, 030227 psychiatry, Position paper, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: The unpredictability and uncertainty of the COVID-19 pandemic; the associated lockdowns, physical distancing, and other containment strategies; and the resulting economic breakdown could increase the risk of mental health problems and exacerbate health inequalities. Preliminary findings suggest adverse mental health effects in previously healthy people and especially in people with pre-existing mental health disorders. Despite the heterogeneity of worldwide health systems, efforts have been made to adapt the delivery of mental health care to the demands of COVID-19. Mental health concerns have been addressed via the public mental health response and by adapting mental health services, mostly focusing on infection control, modifying access to diagnosis and treatment, ensuring continuity of care for mental health service users, and paying attention to new cases of mental ill health and populations at high risk of mental health problems. Sustainable adaptations of delivery systems for mental health care should be developed by experts, clinicians, and service users, and should be specifically designed to mitigate disparities in health-care provision. Thorough and continuous assessment of health and service-use outcomes in mental health clinical practice will be crucial for defining which practices should be further developed and which discontinued. For this Position Paper, an international group of clinicians, mental health experts, and users of mental health services has come together to reflect on the challenges for mental health that COVID-19 poses. The interconnectedness of the world made society vulnerable to this infection, but it also provides the infrastructure to address previous system failings by disseminating good practices that can result in sustained, efficient, and equitable delivery of mental health-care delivery. Thus, the COVID-19 pandemic could be an opportunity to improve mental health services. CM and CA are co-financed by the European Regional Development Fund; have received support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/02227, and PI19/024), the European Commission; CIBERSAM, the Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña; and have received European Union Structural Funds via the European Union Seventh Framework (FP7-4-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2013-2.2.1-2-603196, and FP7-HEALTH-2013-2.2.1-2-602478) and the European Union H2020 programme under the Innovative Medicines Initiative 2 Joint Undertaking (115916 and 777394). TW acknowledges support from the National Institute for Health Research Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London (IS-BRC-1215-20018) and the National Institute for Health Research Senior Investigator Award (NF-SI-0514-10028). MRP acknowledges support from the National Natural Science Foundation of China (81371502 and 81761128031). EV acknowledges the support of the Spanish Ministry of Science and Innovation (PI15/00283 and PI18/00805), funding that was integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional; the Instituto de Salud Carlos III; CIBERSAM; the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017 SGR 1365); the CERCA Programme; and the Departament de Salut de la Generalitat de Catalunya (PERIS grant SLT006/17/00357). MC is supported by a European Research Council Consolidator Award (iHear 724809). We acknowledge Giulia Maria Giordano (University of Campania “Luigi Vanvitelli”, Naples, Italy) and Pasquale Pezzella (University of Campania “Luigi Vanvitelli”, Naples, Italy).
Published: 2020
Full Text: View/download PDF

35. Hypothermie secondaire aux antipsychotiques : à propos d’un cas

Author: Nora Hamdani, N. Drancourt, A. Laguerre, S. Hotier, Y. Mongin, R. Arditti, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Fondation FondaMental [Créteil], Hôpital Sainte-Anne-Université Paris Cité (UPCité), and Hôpital Sainte-Anne-Université Paris Cité (UPC)
Subjects: 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, Arts and Humanities (miscellaneous), business.industry, [SDV]Life Sciences [q-bio], Medicine, business, 030217 neurology & neurosurgery, 030227 psychiatry
Published: 2020
Full Text: View/download PDF

36. Réactivité et pérennité des soins psychiatriques en France à l’épreuve du COVID-19

Author: Claire Jansen, Vincent Laprevote, P. Gorwood, P Gayet, R Bocher, Département d'addictologie et de psychiatrie de liaison [CHU de Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Psychothérapique de Nancy-Unité D, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Hôpital psychiatrique de Nancy, GHU Paris Psychiatrie et Neurosciences, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Martinez Rico, Clara, and Hôpital Sainte-Anne-Université Paris Cité (UPCité)
Subjects: Hospitals, Psychiatric, [SDV]Life Sciences [q-bio], [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Health Services Accessibility, [SCCO]Cognitive science, 0302 clinical medicine, Ambulatory Care, Hospitalisation, Bed Conversion, Social Change, Psychiatry, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Mental Disorders, Organisation des soins, SARS-COV-2, Telemedicine, 3. Good health, [SDV] Life Sciences [q-bio], Hospitalization, Psychiatry and Mental health, France, Coronavirus Infections, Mental Health Services, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Health Personnel, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Article, Betacoronavirus, 03 medical and health sciences, Arts and Humanities (miscellaneous), Political science, Patients' Rooms, Humans, Health system, Pandemics, Occupational Health, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, COVID-19, [SCCO] Cognitive science, 030227 psychiatry, Psychotherapy, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Hospital Restructuring, Humanities, Stress, Psychological, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Psychiatrie
Abstract: Resume Objectifs Les brusques remaniements du systeme de soins lies au COVID-19 touchent particulierement l’organisation de la psychiatrie. Cette revue a pour objectif d’examiner les adaptations des soins psychiatriques en France pendant cette epidemie. Methode Cette revue narrative est basee sur l’observation des changements effectues dans les etablissements francais et sur une analyse de la litterature. Resultats Sur le plan hospitalier, l’epidemie de COVID-19 a impose des mesures modifiant profondement les conditions d’accueil des patients, obligeant les equipes medicosoignantes a adapter leurs methodes de soins. Les auteurs notent la creation d’au moins 89 unites specifiquement dediees aux patients avec COVID-19 ayant besoin de soins psychiatriques, permettant une double prise en charge de medecine generale et de psychiatrie. Concernant les soins ambulatoires, la priorite est de ne pas perdre de vue les patients ayant un suivi au long cours : des moyens de rappel des patients et de teleconsultation ont ete un precieux recours mais ne peuvent entierement remplacer les consultations presentielles. Discussion Dans une situation inedite de bouleversements de grande ampleur du systeme de soins et de la societe, et malgre l’absence de recommandations sur le sujet, la psychiatrie en France a fait preuve d’une tres grande adaptabilite. Certains changements inities pourraient inspirer les soins de l’apres COVID-19.
Published: 2020
Full Text: View/download PDF

37. The consequences of the COVID-19 pandemic on mental health and implications for clinical practice

Author: Philip Gorwood, Andrea Fiorillo, Università degli studi della Campania 'Luigi Vanvitelli', GHU Paris Psychiatrie et Neurosciences, Clinique des Maladies Mentales et de l'Encéphale [Paris] (CMME), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Fiorillo, A., Gorwood, P., Università degli studi della Campania 'Luigi Vanvitelli' = University of the Study of Campania Luigi Vanvitelli, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and Bodescot, Myriam
Subjects: medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Pneumonia, Viral, MEDLINE, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Pandemic, medicine, Humans, 030212 general & internal medicine, Intensive care medicine, Pandemics, ComputingMilieux_MISCELLANEOUS, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Psychiatry, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Betacoronaviru, biology, SARS-CoV-2, Coronavirus Infection, COVID-19, biology.organism_classification, medicine.disease, Mental health, 3. Good health, Clinical Practice, Psychiatry and Mental health, Pneumonia, Editorial, Mental Health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Coronavirus Infections, Psychology, 030217 neurology & neurosurgery, Human
Abstract: International audience
Published: 2020
Full Text: View/download PDF

38. Activation syndrome induced by the antidepressant tianeptine and suicidal ideation: Evidence from a large depressed outpatient sample

Author: Philip Gorwood, Philippe Courtet, Isabelle Jaussent, Jorge Lopez-Castroman, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centro de Investigación Biomédica en Red Salud Mental [Madrid] (CIBER-SAM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université de Paris (UP), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CCSD, Accord Elsevier, and Hôpital Sainte-Anne-Université Paris Cité (UPCité)
Subjects: Male, MESH: Thiazepines, Time Factors, Thiazepines, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Antidepressive Agents, Tricyclic, Anxiety, Benzodiazepines, 0302 clinical medicine, Sleep Initiation and Maintenance Disorders, Outpatients, Tianeptine, MESH: Syndrome, Suicidal ideation, Psychomotor Agitation, MESH: Middle Aged, MESH: Suicidal Ideation, Confounding, MESH: Psychomotor Agitation, Syndrome, Middle Aged, 3. Good health, Suicidal behavior, Activation syndrome, Antidepressant, Drug Therapy, Combination, Female, MESH: Impulsive Behavior, medicine.symptom, medicine.drug, medicine.medical_specialty, [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, MESH: Depressive Disorder, Major, Impulsivity, Suicidal Ideation, 03 medical and health sciences, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, MESH: Sleep Initiation and Maintenance Disorders, medicine, Humans, Psychiatry, Biological Psychiatry, Jitteriness, Pharmacology, Depressive Disorder, Major, MESH: Humans, MESH: Anxiety, business.industry, MESH: Time Factors, medicine.disease, MESH: Male, 030227 psychiatry, MESH: Antidepressive Agents, Tricyclic, MESH: Outpatients, MESH: Drug Therapy, Combination, MESH: Benzodiazepines, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Impulsive Behavior, business, Sleep, MESH: Female
Abstract: Objective To determine the characteristics of the activation syndrome (AS) that predict the emergence or worsening of suicidal ideation (SI) in the first month of antidepressant treatment with tianeptine, as well as the temporal relationship between both conditions. Method A naturalistic sample of 2422 depressed outpatients starting a new antidepressant treatment with tianeptine was assessed at 2, 4 and 6 weeks of follow-up using validated questionnaires. Four main dimensions of AS were examined: impulsivity, sleep problems, anxiety and agitation. Results The emergence of an AS was more likely in long-lasting depressive episodes, but less likely if the patient responded to the antidepressant or benzodiazepines were added as an add-on treatment. Treatment-emergent SI was strongly associated to the presence of an AS, particularly in case of sleep problems (OR = 8.42) or impulsivity upsurges (OR = 3.89), even after adjustment for all relevant confounding factors. Conclusions Our findings suggest a dose-effect mechanism modulating the relationship between treatment-related SI and AS. AS symptoms may need to be monitored closely in the weeks that follow the introduction of an antidepressant treatment.
Published: 2020
Full Text: View/download PDF

39. The relationship between moderate to vigorous physical activity and cognitive rigidity in anorexia nervosa

Author: Laura Di Lodovico, Philip Gorwood, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), and CCSD, Accord Elsevier
Subjects: Adult, Male, Persistence (psychology), Anorexia Nervosa, Adolescent, [SDV]Life Sciences [q-bio], Trail Making Test, Pilot Projects, behavioral disciplines and activities, Young Adult, 03 medical and health sciences, Cognition, 0302 clinical medicine, Thinness, mental disorders, medicine, Humans, Attention, Young adult, Exercise, Biological Psychiatry, Drive, 2. Zero hunger, Principal Component Analysis, Cognitive flexibility, medicine.disease, 030227 psychiatry, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Malnutrition, Anorexia nervosa (differential diagnoses), Case-Control Studies, Female, Observational study, Underweight, medicine.symptom, Psychology, 030217 neurology & neurosurgery, Clinical psychology
Abstract: International audience; A drive for physical activity despite underweight is a core feature of anorexia nervosa. This pilot study detects which aspect of physical activity, if any, could be related to cognitive rigidity in anorexia nervosa. Twenty-eight outpatients with anorexia nervosa and 24 healthy participants were assessed for cognitive flexibility with the Trail Making Test (TMT) and for multiple dimensions of physical activity by subjective and objective assessments. Correlation analysis was conducted to disentangle the relationship between cognitive rigidity and the different aspects of physical activity, then, the moderating effect of anorexia nervosa on this relationship was assessed. A principal component analysis was performed to incorporate all variables of physical activity in (a) global factor(s) reflecting the multidimensional nature of this construct. Cognitive rigidity (TMT b - a score) was significantly correlated to the amount of objectively assessed physical activity estimated, only in the sample of patients with anorexia nervosa. The principal component analysis confirms the correlation between a single construct of "physical activity" and cognitive rigidity in anorexia nervosa only. This pilot study suggests a relationship between cognitive rigidity and physical activity that could help explain the persistence of the latter despite ongoing malnutrition in patients with anorexia nervosa.
Published: 2020
Full Text: View/download PDF

40. Bright Light Therapy in the Morning or at Mid-Day in the Treatment of Non-Seasonal Bipolar Depressive Episodes (LuBi): Study Protocol for a Dose Research Phase I / II Trial

Author: Michel Lejoyeux, Philip Gorwood, Frank Bellivier, Julia Maruani, Ali Amad, Guillaume Vaiva, Bruno Etain, Sylvie Chevret, Caroline Dubertret, Philippe Courtet, Pierre-Alexis Geoffroy, El Mountacer Billah El Abbassi, Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint Louis [APHP], Fondation FondaMental [Créteil], GHU Paris Psychiatrie et Neurosciences, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Paris Diderot - Paris 7 (UPD7), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hopital Louis Mourier - AP-HP [Colombes], Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Equipe 2 : ECSTRA - Epidémiologie Clinique, STatistique, pour la Recherche en Santé (CRESS - U1153), Université Paris Diderot - Paris 7 (UPD7)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Louis Mourier - AP-HP [Colombes], Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Centre de Psychiatrie et Neurosciences (U894), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM)
Subjects: Pediatrics, medicine.medical_specialty, medicine.drug_class, [SDV]Life Sciences [q-bio], Bipolar depression, Major depressive episode, Placebo, Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Bipolar disorders, medicine, Circadian rhythms, Bipolar disorder, Bright light therapy, Biological Psychiatry, Morning, business.industry, Mood stabilizer, Phototherapy, medicine.disease, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, Phase i ii, Cohort, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract: Objective This study protocol aims to determine, using a rigorous approach in patients with bipolar disorder (BD) and non-seasonal major depressive episode (MDE), the characteristics of bright light therapy (BLT) administration (duration, escalation, morning and mid-day exposures) depending on the tolerance (hypomanic symptoms). Methods Patients with BD I or II and treated by a mood stabilizer are eligible. After 1 week of placebo, patients are randomized between either morning or mid-day exposure for 10 weeks of active BLT with glasses using a dose escalation at 7.5, 10, 15, 30 and 45 minutes/day. A further follow-up visit is planned 6 months after inclusion. Patients will be included by cohorts of 3, with at least 3 days of delay between them, and 1 week between cohorts. If none meet a dose limiting toxicity (DLT; i.e hypomanic symptoms), the initiation dose of the next cohort will be increased. If one patient meet a DLT, an additionnal cohort will start at the same dose. If 2 or 3 patients meet a DLT, from the same cohort or from two cohorts at the same dose initiation, the maximum tolerated dose is defined. This dose escalation will also take into account DLTs observed during the intra-subject escalation on previous cohorts, with a "Target Ceiling Dose" defined if 2 DLTs occured at a dose. Discussion Using an innovative and more ergonomic device in the form of glasses, this study aims to better codify the use of BLT in BD to ensure a good initiation and tolerance. Trial registrationaaClinicalTrials.gov Identifier: NCT03396744.
Published: 2018
Full Text: View/download PDF

41. Clinical insight in anorexia nervosa: Associated and predictive factors

Author: Sophie Criquillion, Philip Gorwood, Sébastien Guillaume, Aiste Lengvenyte, Philibert Duriez, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), CCSD, Accord Elsevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Hôpital Sainte-Anne-Université de Paris (UP), and Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Adult, Male, Anorexia Nervosa, Emotions, Baseline level, Anxiety, Anorexia nervosa, Body Mass Index, 03 medical and health sciences, [SCCO]Cognitive science, 0302 clinical medicine, Cognition, Outpatients, medicine, Humans, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Biological Psychiatry, Depression (differential diagnoses), Outcome, 2. Zero hunger, business.industry, Depression, [SCCO] Cognitive science, medicine.disease, Prognosis, 3. Good health, 030227 psychiatry, Cognitive test, Silhouette, Psychiatry and Mental health, Eating disorders, Cognitions, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], medicine.symptom, business, Body mass index, 030217 neurology & neurosurgery, Clinical psychology
Abstract: International audience; Clinical and cognitive factors associated with clinical insight regarding both baseline level and its time-related changes, in outpatients treated for anorexia nervosa. The 193 participants were recruited at 13 French centers specializing in eating disorders (FFAB network) and assessed for insight (SAI-ED), body mass index (BMI), eating disorder severity, symptoms of depression and anxiety, emotional state, silhouette, and functionality; two cognitive tests were also administered. The 137 patients were then re-assessed 18 weeks later. Minimum and ideal subjective BMI and premorbid intelligence were associated with poor baseline insight. Contrary to nearly all other clinical factors, the level of insight revealed no improvement after four months of care. Only the higher value of the minimum lifetime BMI was significantly predictive of increased insight. More positive emotions (PANAS), less symptoms of depression and anxiety (HADS scores), and fewer syndromes (HADS above threshold) were the only factors that covaried with the changes in the level of insight. In conclusion, poor insight has little time variability, contrary to nearly all clinical and cognitive factors. As increased insight is mainly accompanied by improvements in the emotional domain, the latter could represent potential targets for patients with lack of awareness about their eating disorder.
Published: 2019
Full Text: View/download PDF

42. correction : Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity

Author: Bravo-San Pedro, José, Sica, Valentina, Martins, Isabelle, Pol, Jonathan, Loos, Friedemann, Maiuri, Maria Chiara, Durand, Sylvère, Bossut, Noélie, Aprahamian, Fanny, Anagnostopoulos, Gerasimos, Niso-Santano, Mireia, Aranda, Fernando, Ramírez-Pardo, Ignacio, Lallement, Justine, Denom, Jessica, Boedec, Erwan, Gorwood, Philip, Ramoz, Nicolas, Clement, Karine, Pelloux, Véronique, Rohia, Alili, Pattou, François, Raverdy, Violeta, Caiazzo, Robert, Denis, Raphaël, Boya, Patricia, Galluzzi, Lorenzo, Madeo, Frank, Migrenne-Li, Stéphanie, Cruciani-Guglielmacci, Céline, Tavernarakis, Nektarios, López-Otín, Carlos, Magnan, Christophe, Kroemer, Guido, POL, Jonathan, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Gustave Roussy (IGR), Apoptose, cancer et immunité (Equipe labellisée Ligue contre le cancer - CRC - Inserm U1138), Institut Gustave Roussy (IGR)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-École pratique des hautes études (EPHE), Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC), Institut Gustave Roussy (IGR)-Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition et obésités: approches systémiques (UMR-S 1269) (Nutriomics), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Recherche translationnelle sur le diabète - U 1190 (RTD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centro de Investigaciones Biológicas (CSIC), Institute of Molecular Biosciences, Karl-Franzens University Graz, (IMB), Karl-Franzens-Universität Graz, Institute of Molecular Biology and Biotechnology (IMBB), Foundation for Research and Technology, Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo [Oviedo]-Instituto Universitario de Oncología, Laboratoire de physiopathologie de la nutrition (LPN), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur de Shanghai, Académie des Sciences de Chine - Chinese Academy of Sciences (IPS-CAS), Réseau International des Instituts Pasteur (RIIP), Karolinska University Hospital [Stockholm], Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Équipe NutriOmics [Paris], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universidad de Oviedo-Instituto Universitario de Oncología, École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-École Pratique des Hautes Études (EPHE), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), and Centre de Psychiatrie et Neurosciences (U894)
Subjects: [SDV.BC]Life Sciences [q-bio]/Cellular Biology, [SDV.BC] Life Sciences [q-bio]/Cellular Biology
Abstract: International audience; Refers toJosé M. Bravo-San Pedro, Valentina Sica, Isabelle Martins, Jonathan Pol, Friedemann Loos, Maria Chiara Maiuri, Sylvère Durand, Noélie Bossut, Fanny Aprahamian, Gerasimos Anagnostopoulos, Mireia Niso-Santano, Fernando Aranda, Ignacio Ramírez-Pardo, Justine Lallement, Jessica Denom, Erwan Boedec, Philip Gorwood, Nicolas Ramoz, Karine Clément, Veronique Pelloux, Alili Rohia, François Pattou, Violeta Raverdy, Robert Caiazzo, Raphaël G.P. Denis, Patricia Boya, Lorenzo Galluzzi, Frank Madeo, Stéphanie Migrenne-Li, Céline Cruciani-Guglielmacci, Nektarios Tavernarakis, Carlos López-Otín, Christophe Magnan, Guido KroemerAcyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and ObesityCell Metabolism, Volume 30, Issue 4, 1 October 2019, Pages 754-767.e9
Published: 2019
Full Text: View/download PDF

43. Impaired decision-making in symptomatic anorexia and bulimia nervosa patients: a meta-analysis

Author: Sébastien Guillaume, F. van den Eynde, Philippe Courtet, Philip Gorwood, Fabrice Jollant, Stéphane Richard-Devantoy, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Psychiatry [Montréal], McGill University = Université McGill [Montréal, Canada], Laboratoire de Psychologie des Pays de la Loire (LPPL), Université d'Angers (UA)-Université de Nantes - UFR Lettres et Langages (UFRLL), Université de Nantes (UN)-Université de Nantes (UN), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, and McGill University
Subjects: medicine.medical_specialty, Anorexia Nervosa, Decision Making, eating disorders, Anorexia, Neuropsychological Tests, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Binge-eating disorder, Internal medicine, Task Performance and Analysis, Iowa gambling task, medicine, Humans, Bulimia Nervosa, Psychiatry, Applied Psychology, 2. Zero hunger, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Bulimia nervosa, 1. No poverty, medicine.disease, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, Eating disorders, Anorexia nervosa (differential diagnoses), [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Meta-analysis, medicine.symptom, Psychology, Body mass index, Binge-Eating Disorder, 030217 neurology & neurosurgery, Decision-making
Abstract: Background.Impaired decision-making is a potential neurocognitive phenotype of eating disorders. It is therefore important to disentangle the decision-making deficits associated with the eating disorder subtypes and determine whether this putative impairment is a state or trait marker of the disease or more related to starvation. We systematically reviewed the literature on decision-making in eating disorders and conducted a meta-analysis to explore its role in anorexia nervosa (AN), bulimia nervosa (BN) and binge-eating disorder (BED).Method.A search of the Medline and EMBASE databases and article references was performed. A total of 23 studies (2044 participants) met the selection criteria. When the Iowa gambling task (IGT) was used in at least three of the studies, a meta-analysis was run.Results.IGT performance was significantly worse in patients with an eating disorder diagnosis (AN, BN or BED) compared with healthy controls, indicating that eating disorders have a negative effect on decision-making. Hedges’ g effect sizes were moderate to large (−0.72 in AN, −0.62 in BN, and −1.26 in BED). Recovered AN patients had IGT scores similar to those of healthy controls. Restrictive AN patients had significantly lower IGT net scores than purging AN patients, and both AN subtypes had worse performances than healthy controls. Age and body mass index did not explain results.Conclusions.Decision-making was significantly altered in patients with eating disorders. Poor decision-making was more pronounced during the acute phase than in the recovered state of AN. Nutritional status during the acute phase of the disease did not seem to influence decision-making skills.
Published: 2015
Full Text: View/download PDF

44. Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive tests

Author: F. Bayle, Philip Gorwood, M.L. Cléry-Melun, Stéphane Richard-Devantoy, Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne, Department of Psychiatry, McGill University-Douglas Mental Health University Institute, Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique ( SHU ), Assistance publique - Hôpitaux de Paris (AP-HP)-CH Ste Anne, Servier, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), Department of Psychiatry [Montréal], McGill University = Université McGill [Montréal, Canada], Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique (SHU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CH Ste Anne, and Gorwood, Philip
Subjects: Male, Pediatrics, medicine.medical_specialty, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Trail Making Test, Clinical Neurology, Major depressive disorder, Neuropsychological Tests, Severity of Illness Index, Cognition, Scar, Recurrence, Acetamides, medicine, Humans, Dementia, Agomelatine, Attention, Pharmacology (medical), Biological Psychiatry, Pharmacology, Depressive Disorder, Psychomotor retardation, Neurotoxic, Middle Aged, medicine.disease, Antidepressive Agents, Cognitive test, Psychiatry and Mental health, Neurology, Cognitive remediation therapy, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Female, Neurology (clinical), medicine.symptom, Psychology, Neurocognitive, Psychomotor Performance, Follow-Up Studies, Clinical psychology, medicine.drug
Abstract: International audience; : The cumulative duration of depressive episodes, and their repetition, has a detrimental effect on depression recurrence rates and the chances of antidepressant response, and even increases the risk of dementia, raising the possibility that depressive episodes could be neurotoxic. Psychomotor retardation could constitute a marker of this negative burden of past depressive episodes, with conflicting findings according to the use of clinical versus cognitive assessments. We assessed the role of the Retardation Depressive Scale (filled in by the clinician) and the time required to perform the neurocognitive d2 attention test and the Trail Making Test (performed by patients) in a sample of 2048 depressed outpatients, before and after 6 to 8 weeks of treatment with agomelatine. From this sample, 1140 patients performed the TMT-A and -B, and 508 performed the d2 test, at baseline and after treatment. At baseline, we found that with more past depressive episodes patients had more severe clinical level of psychomotor retardation, and that they needed more time to perform both d2 and TMT. When the analyses were performed again after treatment, and especially when the analyses were restricted to patients with clinical remission, the cognitive tests were the only ones correlated with past depressive episodes. Psychomotor retardation tested at a cognitive level was therefore systematically revealing the burden of past depressive episodes, with an increased weight for patients with less remaining symptoms. If prospectively confirmed, interventions such as cognitive remediation therapy could benefit from a more specific focus on neurocognitive retardation.
Full Text: View/download PDF

45. Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission

Author: Catherine Delva, S. Bouju, Cécile Deal, Charlotte Gary, Pierre-Michel Llorca, Philip Gorwood, Sylvie Lancrenon, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Université de Paris (UP), Service de Psychiatrie de l'Adulte B [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université Paris Cité (UPCité), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), Janssen-Cilag [Issy-les-Moulineaux], Sylia-Stat [Bourg-La-Reine, France], and CCSD, Accord Elsevier
Subjects: Adult, Male, Psychosis, medicine.medical_specialty, Adolescent, [SDV]Life Sciences [q-bio], Symptomatic treatment, Clinical remission, Long-acting injectable antipsychotics, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Outcome Assessment, Health Care, Antipsychotics, Humans, Medicine, In patient, Functioning, Prospective Studies, Stage (cooking), Biological Psychiatry, business.industry, Remission Induction, medicine.disease, 030227 psychiatry, 3. Good health, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Long acting, Functional remission, Schizophrenia, Delayed-Action Preparations, Female, Observational study, business, 030217 neurology & neurosurgery, Antipsychotic Agents
Abstract: International audience; Background: Functional remission has become a major therapeutic objective in schizophrenia, but the probability of such positive outcome has a large variability, ranging from 15% to 51%. Additionally, how clinical remission constitutes a prerequisite for functional remission also remains unclear.Methods: A prospective observational study was conducted in French schizophrenic patients who initiated treatment with a long-acting injectable (LAI) after an acute episode. Functional and clinical remissions were assessed using the FROGS and the Andreasen criteria, and the role of clinical remission and predictive factors of functional remission was evaluated.Results: Three hundred three patients with schizophrenia (DSM-IV criteria) were followed for 12 months. At 12 months, 45.1% of the patients reached functional remission while 55.1% obtained clinical remission. Clinical remission facilitated functional remission (OR = 14.74), especially in patients with psychosis for less than 5 years (OR = 23.73). Other predictive factors concerned the family environment, education level, employment status, baseline functioning levels and level of insight.Conclusions: About half of patients treated with LAI reached functional remission after one year of follow-up. Reduced clinical symptoms and reaching clinical remission largely favored functional remission. These results stress the importance of continuous and appropriate symptomatic treatment to reach functional remission and maximize recovery chances.
Published: 2019
Full Text: View/download PDF

46. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity

Author: Nektarios Tavernarakis, Mireia Niso-Santano, Lorenzo Galluzzi, Violeta Raverdy, Friedemann Loos, Guido Kroemer, François Pattou, Céline Cruciani-Guglielmacci, Patricia Boya, Justine Lallement, Frank Madeo, Jessica Denom, Ignacio Ramírez-Pardo, Karine Clément, Christophe Magnan, Isabelle Martins, Sylvère Durand, Raphaël G. P. Denis, Noélie Bossut, Maria Chiara Maiuri, Véronique Pelloux, Robert Caiazzo, Valentina Sica, Erwan Boedec, Alili Rohia, Stéphanie Migrenne-Li, José Manuel Bravo-San Pedro, Jonathan Pol, Nicolas Ramoz, Fernando Aranda, Philip Gorwood, Gerasimos Anagnostopoulos, Fanny Aprahamian, Carlos López-Otín, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Gustave Roussy (IGR), Université Paris-Saclay, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigaciones Biológicas (CSIC), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition et obésités: approches systémiques (nutriomics) (UMR-S 1269 INSERM - Sorbonne Université), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (GI3M), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Apoptose, cancer et immunité (U848), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Weill Medical College of Cornell University [New York], Sandra and Edward Meyer Cancer Center [New-York], Yale University School of Medicine, BioTechMed-Graz, Graz University of Technology [Graz] (TU Graz)-Medical University Graz-Karl-Franzens-Universität [Graz, Autriche], Institute of Molecular Biosciences, Karl-Franzens-Universität [Graz, Autriche], University of Crete [Heraklion] (UOC), Institute of Molecular Biology and Biotechnology (IMBB-FORTH), Foundation for Research and Technology - Hellas (FORTH), Universidad de Oviedo [Oviedo], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), University of Science & Technology of China [Suzhou], Karolinska Institutet [Stockholm], The authors thank CRC Core Facilities (CGB, CHIC, and CEF). G.K. is supported by the Ligue Contre le Cancer (équipe labelisée), Agence National de la Recherche (ANR) – projets blancs, Cancéropôle Île-de-France, Chancelerie Des universités de Paris (Legs Poix), the European Research Council (ERC), Inserm Transfert, Fondation Carrefour, Institut National du Cancer (INCa), Inserm (HTE), Institut Universitaire de France, Leducq Foundation, the Labex immuno-Oncology, the RHU Torino Lumière, the Seattle Foundation, and the SIRICs SOCRATE and CARPEM. C.M. and C.C.-G. are supported by Agence National de la Recherche (ANR-16-CE14-0026, fat4brain proposal), C.L.-O. is supported by 'Juan de Madariaga fellowship', S.B. is supported by the Swedish Research Council Vetenskapsrådet (2015-05468) and the Austrian Science Fund FWF (P27183-B24), and F.M. is supported by the Austrian Science Fund FWF (grants P23490-B20, P29262, P24381, P29203, and P27893), DKplus Metabolic and Cardiovascular Diseases (W1226), Austrian Science Ministry, Karl Franzens University ('Unkonventionelle Forschung' and 'flysleep'), NAWI Graz, and BioTechMed-Graz flagship project 'EPIAge.' K.C. is supported by ANR MICRO-Obes and AP/HP (PHRC Microbaria). L.G. is supported by an intramural startup from the Department of Radiation Oncology of Weill Cornell Medical College (New York, US) and by Sotio a.c. (Prague, Czech Republic)., The authors thank PreclinICAN (Institute of Cardiometabolism and Nutrition, IHU-ICAN, Paris, France) and 'Plateforme Imageries du Vivant' INSERM UMR 970 (PARCC-HEGP) for analyses of mouse whole-body composition and Functional & Physiological Exploration Platform (FPE) of the Unit 'Biologie Fonctionnelle et Adaptative' (University Paris Diderot, Sorbonne Paris Cité, BFA, UMR 8251 CNRS, Paris, France) for metabolic analyses., Ligue Nationale contre le Cancer (France), Agence Nationale de la Recherche (France), Chancellerie des Universités de Paris, European Research Council, Institut National du Cancer (France), Fondation Leducq, Swedish Research Council, Austrian Science Fund, Federal Ministry of Science, Research and Economy (Austria), Bravo-San-Pedro, José Manuel [0000-0002-5781-1133], Sica, Valentina [0000-0003-2770-5847], Martins, Isabelle [0000-0003-0885-613X], Pol, Jonathan G. [0000-0002-8355-7562], Loos, Friedemann [0000-0002-5976-5978], Maiuri, Maria Chiara [0000-0001-9760-7674], Niso-Santano, Mireia [0000-0002-6506-422X], Aranda, Fernando [0000-0002-9364-474X], Gorwood, Philip [0000-0003-1845-3676], Ramoz, Nicolas [0000-0002-8070-9938], Cleḿent, Karine [0000-0002-2489-3355], Pelloux, Véronique [0000-0003-3630-4746], Raverdy, Violeta [0000-0001-5754-2028], Denis, Raphaël G.P. [0000-0002-7677-7460], Boya, Patricia [0000-0003-3045-951X], Galluzzi, Lorenzo [0000-0003-2257-8500 ], Madeo, Frank [0000-0002-5070-1329], Cruciani-Guglielmacci, Céline [0000-0002-2562-5360], Tavernarakis, Nektarios [0000-0002-5253-1466 ], López-Otín, Carlos [0000-0001-6964-1904], Magnan, Christophe [0000-0002-7044-2571], Kroemer, Guido [0000-0002-9334-4405], CCSD, Accord Elsevier, Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Nutrition et obésités: approches systémiques (UMR-S 1269) (Nutriomics), Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (EGENODIA (GI3M)), Yale School of Medicine [New Haven, Connecticut] (YSM), Graz University of Technology [Graz] (TU Graz)-Karl-Franzens-Universität Graz-Medical University Graz, Karl-Franzens-Universität Graz, École Pratique des Hautes Études (EPHE), Centre de Psychiatrie et Neurosciences (U894), ANR-16-CE14-0026,Fat4Brain,Le métabolisme des lipides dans le cerveau est un regulateur essentiel de l'homéostasie énergétique(2016), Bravo-San Pedro, J. M., Sica, V., Martins, I., Pol, J., Loos, F., Maiuri, M. C., Durand, S., Bossut, N., Aprahamian, F., Anagnostopoulos, G., Niso-Santano, M., Aranda, F., Ramirez-Pardo, I., Lallement, J., Denom, J., Boedec, E., Gorwood, P., Ramoz, N., Clement, K., Pelloux, V., Rohia, A., Pattou, F., Raverdy, V., Caiazzo, R., Denis, R. G. P., Boya, P., Galluzzi, L., Madeo, F., Migrenne-Li, S., Cruciani-Guglielmacci, C., Tavernarakis, N., Lopez-Otin, C., Magnan, C., Kroemer, G., Bravo-San-Pedro, José Manuel, Sica, Valentina, Martins, Isabelle, Pol, Jonathan G., Loos, Friedemann, Maiuri, Maria Chiara, Niso-Santano, Mireia, Aranda, Fernando, Gorwood, Philip, Ramoz, Nicolas, Cleḿent, Karine, Pelloux, Véronique, Raverdy, Violeta, Denis, Raphaël G.P., Boya, Patricia, Galluzzi, Lorenzo, Madeo, Frank, Cruciani-Guglielmacci, Céline, Tavernarakis, Nektarios, López-Otín, Carlos, Magnan, Christophe, and Kroemer, Guido
Subjects: Male, 0301 basic medicine, obesity, Anorexia Nervosa, Physiology, Mice, Obese, Weight Gain, Eating, Mice, 0302 clinical medicine, lipid metabolism, Acyl-CoA-binding protein, Beta oxidation, media_common, Diazepam Binding Inhibitor, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, 2. Zero hunger, 0303 health sciences, Leptin Deficiency, Chemistry, Fatty Acids, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Anorexia, 3. Good health, anorexia, Lipogenesis, Female, medicine.symptom, Human, autophagy, medicine.medical_specialty, media_common.quotation_subject, Context (language use), Cell Line, 03 medical and health sciences, Internal medicine, Macroautophagy, Weight Loss, Autophagy, medicine, Animals, Humans, Obesity, Molecular Biology, 030304 developmental biology, Animal, Lipogenesi, Appetite, Cell Biology, Weight Lo, Mice, Inbred C57BL, Lipid metabolism, 030104 developmental biology, Endocrinology, Fatty Acid, 030217 neurology & neurosurgery
Abstract: 24 p.-6 fig.-1 tab.-1 graph. abst., Autophagy facilitates the adaptation to nutritional stress. Here, we show that short-term starvation of cultured cells or mice caused the autophagy-dependent cellular release of acyl-CoA-binding protein (ACBP, also known as diazepam-binding inhibitor, DBI) and consequent ACBP-mediated feedback inhibition of autophagy. Importantly, ACBP levels were elevated in obese patients and reduced in anorexia nervosa. In mice, systemic injection of ACBP protein inhibited autophagy, induced lipogenesis, reduced glycemia, and stimulated appetite as well as weight gain. We designed three approaches to neutralize ACBP, namely, inducible whole-body knockout, systemic administration of neutralizing antibodies, and induction of antiACBP autoantibodies in mice. ACBP neutralization enhanced autophagy, stimulated fatty acid oxidation, inhibited appetite, reduced weight gain in the context of a high-fat diet or leptin deficiency, and accelerated weight loss in response to dietary changes. In conclusion, neutralization of ACBP might constitute a strategy for treating obesity and its co-morbidities., G.K. is supported by the Ligue Contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR) – projets blancs; Cancéropôle Île-de-France; Chancelerie Des universités de Paris (Legs Poix); the European Research Council (ERC); Inserm Transfert, Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; Leducq Foundation; the Labex immuno-Oncology; the RHU Torino Lumière; the Seattle Foundation; and the SIRICs SOCRATE and CARPEM. C.M. and C.C.-G. are supported by Agence National de la Recherche (ANR-16-CE14-0026, fat4brain proposal); C.L.-O. is supported by “Juan de Madariaga fellowship”; S.B. is supported by the Swedish Research Council Vetenskapsrådet (2015-05468) and the Austrian Science Fund FWF (P27183-B24); and F.M. is supported by the Austrian Science Fund FWF (grants P23490-B20, P29262, P24381, P29203, and P27893), DKplus Metabolic and Cardiovascular Diseases (W1226), Austrian Science Ministry, Karl Franzens University (“Unkonventionelle Forschung” and “flysleep”), NAWI Graz, and BioTechMed-Graz flagship project “EPIAge.” K.C. is supported by ANR MICRO-Obes and AP/HP (PHRC Microbaria). L.G. is supported by an intramural startup from the Department of Radiation Oncology of Weill Cornell Medical College (New York, US) and by Sotio a.c. (Prague, Czech Republic).
Published: 2019
Full Text: View/download PDF

47. Neurotrophin Genes and Antidepressant-Worsening Suicidal Ideation: A Prospective Case-Control Study

Author: Tatyana Shekhtman, Philip Gorwood, Géraldine Voegeli, John R. Kelsoe, Philippe Courtet, Nicolas Ramoz, Herrada, Anthony, Analyse Phenotypique, Developpementale et Genetique des Comportements Addictifs, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, University of California [San Diego] (UC San Diego), University of California (UC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), University of California, and Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Suicide Prevention, Male, Antidepressant drugs, Pharmacogenomic Variants, Thiazepines, neutrotrophin, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Medical and Health Sciences, 0302 clinical medicine, Gene Frequency, Risk Factors, Ambulatory Care, Pharmacology (medical), Prospective Studies, Prospective cohort study, Suicidal ideation, Depression (differential diagnoses), pharmacogenetics, Psychiatry, Membrane Glycoproteins, Depression, Brief Report, Single Nucleotide, Middle Aged, Serious Mental Illness, Antidepressive Agents, 3. Good health, Psychiatry and Mental health, Suicide, Mental Health, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Cohort, trkB, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, medicine.symptom, Psychology, Receptor, Adult, medicine.medical_specialty, Neutrotrophin, Single-nucleotide polymorphism, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, Polymorphism, Single Nucleotide, Suicidal Ideation, 03 medical and health sciences, Internal medicine, medicine, Genetics, Receptor, trkB, Humans, antidepressant drugs, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Polymorphism, suicide, Aged, Pharmacology, Suicide attempt, Prevention, Brain-Derived Neurotrophic Factor, Psychology and Cognitive Sciences, Case-control study, 030227 psychiatry, Brain Disorders, Pharmacogenomic Testing, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Haplotypes, Pharmacogenetics, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Case-Control Studies, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, 030217 neurology & neurosurgery
Abstract: International audience; BACKGROUND: Antidepressant-worsening suicidal ideation is a rare but serious phenomenon. This study aimed to test for association between antidepressant-worsening suicidal ideation and polymorphisms of BDNF/NTRK2 neurotrophin pathway genes, known to be involved in depression and suicide.METHODS: This was a case-control study comparing patients with antidepressant-worsening suicidal ideation to patients without. Patients were collected from the GENESE cohort (3771 depressed tianeptine-treated outpatients). Antidepressant-worsening suicidal ideation was defined by an increase of at least 2 points on the Montgomery-Åsberg Depression Rating Scale-item10 during treatment. Controls were matched for age, sex, and baseline Montgomery-Åsberg Depression Rating Scale-item10 score. Thirteen single nucleotide polymorphisms covering 5 BDNF/NTRK2 pathway genes were genotyped.RESULTS: A total 78 cases and 312 controls were included. Two NTRK2 single nucleotide polymorphisms were associated to antidepressant-worsening suicidal ideation: rs1439050 (P=.01) and rs1867283 (P=.04). Association with rs1439050 remained significant after adjustment for potentially confounding factors, including previous suicide attempts (P
Published: 2016
Full Text: View/download PDF

48. New Insights in Anorexia Nervosa

Author: Sergueï O. Fetissov, Nicolas Ramoz, Carole Rovere-Jovene, Pierre Déchelotte, Nicolas Chartrel, Jean-Claude Melchior, Corinne Blanchet-Collet, Nathalie Godart, Odile Viltart, Philip Gorwood, Virginie Tolle, Mouna Hanachi, Jacques Epelbaum, Jeanne Duclos, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Sainte Anne [Paris], Maison de Solenn [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mutualiste de Montsouris (IMM), Cognition, Santé, Société (C2S), SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Maison des Sciences Humaines de Champagne-Ardenne (MSH-URCA), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées (END-ICAP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Raymond Poincaré [AP-HP], Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), Université Sorbonne Paris Cité (USPC), Laboratoire Mémoire et Cognition, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), douville, sabine, Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-Maison des Sciences Humaines de Champagne-Ardenne (MSH-URCA), Centre de Psychiatrie et Neurosciences (U894), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Dept. of Psychiatry for Adolescents and Young Adults, Faculté de Médecine, Site Institut Mutualiste Montsouris, Université Paris Descartes - Paris 5 (UPD5), Appareil Digestif Environnement Nutrition (ADEN), Normandie Université (NU)-Normandie Université (NU), AP-HP Hôpital Raymond Poincaré [Garches], Analyse Phenotypique, Developpementale et Genetique des Comportements Addictifs, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), CRM J-P Aubert INSERM UMR 837, and Université de Lille
Subjects: 0301 basic medicine, reward system adaptations, Lateral hypothalamus, autoantibodies, [SDV]Life Sciences [q-bio], mental homeostasis, Review, eating disorders, Gut flora, Developmental psychology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Neuroimaging, Orexigenic, medicine, microbiota, ComputingMilieux_MISCELLANEOUS, biology, General Neuroscience, Cognition, biology.organism_classification, medicine.disease, 3. Good health, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Eating disorders, 030104 developmental biology, Anorexia nervosa (differential diagnoses), susceptibility factors, Abnormality, Psychology, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Neuroscience, 030217 neurology & neurosurgery, medicine.drug
Abstract: International audience; Anorexia nervosa (AN) is classically defined as a condition in which an abnormally low body weight is associated with an intense fear of gaining weight and distorted cognitions regarding weight, shape, and drive for thinness. This article reviews recent evidences from physiology, genetics, epigenetics, and brain imaging which allow to consider AN as an abnormality of reward pathways or an attempt to preserve mental homeostasis. Special emphasis is put on ghrelino-resistance and the importance of orexigenic peptides of the lateral hypothalamus, the gut microbiota and a dysimmune disorder of neuropeptide signaling. Physiological processes, secondary to underlying, and premorbid vulnerability factors—the “pondero-nutritional-feeding basements”- are also discussed.
Published: 2016
Full Text: View/download PDF

49. Determinants of early identification of suicidal ideation in patients treated with antidepressants or anxiolytics in general practice: a multilevel analysis.: Early identification of suicidal ideation

Author: Rémy Sebbah, Pierre Verger, Pierre-Alexis Brabis, Frédéric Rouillon, Alain Paraponaris, Viviane Kovess, Anne M. Lovell, Patrick Villani, ORS PACA, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation de santé publique, MGEN, Centre de Recherche Psychotropes, Santé Mentale, Société (CESAMES), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Médecin généraliste, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Southeastern France Regional Union of Private Practitioners (URML PACA), Funds for quality insurance of private medical care (FAQSV-URCAM-PACA), Foundation for Public health of the MGEN, Southeastern Regional Direction for Sanitary and Social Affairs (DRASS-PACA), 2002 call for proposals of CNRS/MIRE/DREES/INSERM., and Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)
Subjects: Male, Suicide Prevention, Personality Inventory, Continuing medical education, Poison control, Personality Assessment, Hospital Anxiety and Depression Scale, Suicide prevention, 0302 clinical medicine, MESH: Risk Factors, MESH: Early Diagnosis, Risk Factors, Suicidal ideation, 030212 general & internal medicine, Referral and Consultation, Depression (differential diagnoses), MESH: Aged, MESH: Middle Aged, MESH: Curriculum, Middle Aged, Anxiety Disorders, Antidepressive Agents, 3. Good health, Suicide, Psychiatry and Mental health, Clinical Psychology, Education, Medical, Continuing, Female, Curriculum, medicine.symptom, General practice, Family Practice, Adult, medicine.medical_specialty, Psychotropic drugs, Adolescent, MESH: Depressive Disorder, Major, Multilevel model, MESH: Personality Assessment, MESH: Referral and Consultation, 03 medical and health sciences, Injury prevention, medicine, Humans, Medical prescription, Psychiatry, MESH: Family Practice, Aged, MESH: Adolescent, Depressive Disorder, Major, MESH: Humans, business.industry, MESH: Adult, MESH: Education, Medical, Continuing, MESH: Male, 030227 psychiatry, MESH: Anti-Anxiety Agents, MESH: Personality Inventory, MESH: Suicide, Early Diagnosis, Anti-Anxiety Agents, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, MESH: Anxiety Disorders, MESH: Antidepressive Agents, business, MESH: Female
Abstract: International audience; BACKGROUND: General practitioners (GPs) play a key role in identifying and managing patients with suicidal tendencies. Few studies, however, examine both GP and patient characteristics and GP practices associated with suicide assessment. This article aims to evaluate 1) GPs' success in early identification of suicidal ideation (SI) in patients starting antidepressant or anxiolytic treatment, and 2) patient- and GP-related factors associated with this success. METHODS: Survey of 144 GPs practising in southeastern France and of consecutive adults consulting them during June-October 2004 and prescribed antidepressant or anxiolytic treatment. Data were collected from GPs (consultation-questionnaires focusing on their prescription, diagnosis and detection of SI) and patients (self-administered questionnaires including the Hospital Anxiety and Depression scale and social and demographic characteristics). We used multilevel logistic regression to analyse factors associated with SI detection. RESULTS: GPs completed consultation-questionnaires for 713 patients, 405 of whom completed self-administered questionnaires. Eighty-nine patients (22%) reported SI; in 43 cases (48%) SI had not been detected by the GP. GPs detected SI more frequently when they had completed continuing medical education about depression, when patients had higher depressive symptom scores, and when consultations were relatively long. LIMITATIONS: Study limited to patients receiving initial prescriptions for antidepressants or anxiolytics. CONCLUSIONS: The percentage of undetected SI in this study population was high. Additional training of GPs increases the chances of detecting SI. Medical training and continuing medical education should include better instruction about SI risk factors and diagnosis, including non-major depressions, and stress that screening requires sufficient consultation time.
Published: 2007
Full Text: View/download PDF

50. An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness

Author: K. Demyttenare, Philip Gorwood, Pierre-Michel Llorca, F. Bayle, P. Courtet, Guillaume Vaiva, Emmanuelle Corruble, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Descartes - Paris 5 (UPD5), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Santé mentale et santé publique (SMSP - U1178), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de Psychiatrie et Neurosciences (U894), and Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Subjects: Male, Treatment response, Psychotherapist, media_common.quotation_subject, Emotions, Major depressive disorder, Sensitivity and Specificity, Surveys and Questionnaires, Acetamides, Outpatients, Replication (statistics), Sadness, medicine, Humans, Hypnotics and Sedatives, Agomelatine, 10. No inequality, media_common, Emotion, Depressive Disorder, Major, Principal Component Analysis, Middle Aged, medicine.disease, Joy, Clinical Practice, Psychiatry and Mental health, Clinical Psychology, Treatment Outcome, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Antidepressant, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Psychology, Prediction, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies, Clinical psychology, medicine.drug
Abstract: International audience; BACKGROUND:Early improvement in positive emotions-more than decreases in negative emotions-was highly predictive of treatment response in an ecologically valid prospective manner. This result needs replication with simpler assessments to determine whether it can be translated into clinical practice.METHODS:2049 adult depressed outpatients receiving agomelatine were assessed at inclusion, week 2, and week 6 using the clinician-rated Quick Inventory of Depressive Symptomatology, Sheehan Disability Scale, Clinical Global Impression scale, and Multidimensional Assessment of Thymic States (MATHYS), an auto-questionnaire rating the frequency of emotions, including sadness and joy, over the previous week.RESULTS:Joy and sadness had a relatively low correlation coefficient at baseline (r=-0.277), joy (r=-0.160) being less correlated with clinical severity than sadness (r=0.317). An increase in joy at week 2 had higher specificity (85.04%) and positive predictive value (70.55%) for treatment response than decreased sadness (57.92% and 66.04%, respectively), and the global capacity of the former to predict remission, either clinical (Yule Q coefficient, 39.96%) or functional (44.35%), was even better compared to the prediction of clinical response (37.38%).LIMITATIONS:MATHYS retrospectively assesses emotions, with five possible ratings only, relying on self-rated frequencies. With only a 6-week follow-up, conclusions are limited to short-term aspects of clinical and functional remission.CONCLUSIONS:Early improvement in joy during the first 2 weeks of treatment is strongly specific for treatment response and remission. The frequency of joy captures the predictivity and may deserve further study regarding inclusion in depressive rating scales.
Published: 2015
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

269 results on '"Clinique des Maladies Mentales et de l'Encéphale"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources